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In the developing vertebrate embryo, multipotent cells of the paraxial
mesoderm form epithelial spheres called somites that physically define the
segmentation pattern of the embryo.

MyoD is transcribed in the myogenic

precursor cells of the developing somite and is essential for proper hypaxial
muscle formation.

Whether MyoD is a determination factor or downstream

member of the myogenic program had yet to be shown and the cis-transcriptional
control of this important gene was incompletely defined.
By permanently labeling cells that have transcribed the MyoD locus in
MyoD-/-/Myf-5-/- embryos, where myogenesis does not occur, the determination
state of presumptive myoblasts has been revealed. Previous studies used a
temporary cell labeling system and suggested that in MyoD-/-/Myf-5-/- embryos,
cells of the MyoD lineage apoptose and do not contribute to other cell types.
This suggests that the MyoD lineage is committed to myogenesis before
myoblasts form. In the results presented herein, cells that have activated the

MyoD locus persist until birth and contribute to bone, brown adipose tissue and
connective tissue demonstrating the multipotent nature of premyogenic cells prior
to MyoD activation.
The genetic regulatory elements controlling MyoD expression were
thought to be the core enhancer (CE) and distal regulatory region (DRR), where
the CE initiates MyoD expression and the DRR maintains it. Deletion of either
the CE or DRR from the mouse genome resulted in only mild phenotypes and
suggested more complexity in MyoD regulation. Here, we deleted both the CE
and DRR to determine if the enhancers have compensatory abilities or if other
unknown regulatory elements exist. In situ hybridization for MyoD mRNA in our
new line of mouse embryos shows that removal of both enhancers does not
seriously alter the MyoD expression profile.

The phenotypes seen in the

individual knockout embryos are both present when the CE and DRR are
removed. Genomic database analysis implicates the introns of MyoD as the
uncharacterized enhancers.
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Chapter 1: Introduction

Skeletal myogenesis is vital for motility, and the transcriptional regulation of a
potent myogenic transcription factor, MyoD, and the determination state of
embryonic cells poised to enter the myogenic program have yet to be fully
explained.

This thesis focuses on MyoD in the hopes that basic scientific

knowledge of its function and regulatory elements can advance the field toward a
more nuanced understanding of myogenesis.

This introduction will provide

background knowledge on the genes involved and the process of embryonic
myogenesis.

1.1 Identification of the Myogenic Regulatory Factors:

Embryologists, and now stem cell biologists, have been interested in
finding what gene products could convert multipotent progenitor cells to become
developmentally restricted to a single cell type.

Early insight into the genes

controlling skeletal muscle formation was gleaned by experiments where 10T1/2
fibroblasts were converted to differentiated skeletal muscle cells by treatment
with the DNA demethylating agent 5-azacytidine (Constantinides, 1977).

5-

azacytidine is a cytosine nucleotide analog that can not be methylated and was
introduced into dividing fibroblasts. To find what transcripts were responsible for
the phenotypic change in fibroblasts, subtractive hybridization was performed
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between the two populations, revealing a cDNA, that when ectopically expressed,
was capable of converting 10T1/2 fibroblasts, nerve, pigment, fat, and liver cells
muscle (Davis et al., 1987; Weintraub et al., 1989). The gene activated due loss
of methylation and responsible for the fate switches when over expressed was
named MyoD for ‘myogenic determination gene’.
Subsequent to the identification of MyoD, three other genes possessing
the ability to convert non-muscle cells to muscle were identified.

Looking for

related transcription factors, MyoD cDNA was used as a probe in low stringency
conditions to fish for transcripts in myogenic cells lines and from mRNA extracted
from adult rat muscle.

The three genes found were, Myogenin (Olson et al.,

1990; Wright et al., 1989), Myf-5 (Braun et al., 1989), and Mrf4(Braun et al.,
1990; Miner and Wold, 1990). These four genes are expressed only in skeletal
muscle or mesodermal precursor cells and encode highly related transcription
factors containing 95% amino acid homology within a centrally located 70 amino
acid basic helix-loop-helix (bHLH) domain which is necessary for DNA binding
and dimerization (Ishibashi et al., 2005; Olson et al., 1990).

1.2 Myogenic Regulatory Factor Function:

Formation of function skeletal muscle occurs via two broad phases,
determination and differentiation.

Determination occurs when a multipotent

progenitor becomes committed to the myogenic fate and contributes to the
proliferative progenitor pool of myoblasts. During differentiation, myoblasts fuse
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with each other to form multinucleated myotubes that will eventually become
muscle fibers.
Muscle based mobility is essential for life in non-sedentary organisms and
there would be no muscle fibers without the determination of the myogenic
lineage and formation of myoblasts. MyoD, Myf-5, and Mrf4 are the three genes
currently shown to be involved in myoblast formation. Absence of the protein
products from the MyoD, Myf-5, and Mrf4 genes in the developing mouse embryo
results in new born mice devoid of skeletal muscle (Rudnicki et al., 1993).
Importantly, not only was mature skeletal muscle absent, but cells expressing
markers of myoblasts, the single cell proliferative precursors of muscle fibers,
were absent as well (Kablar et al., 2003). The original Myf-5 knock out allele,
Myf-5Neo, unknowingly blocking transcription of Mrf4 during early development
(Kassar-Duchossoy et al., 2004). A more recent knock out allele, Myf-5loxP, does
not affect Mrf4 transcription and paraxial mesoderm cells form myosin heavy
chain positive muscle cells in the absence of only MyoD and Myf-5. However,
Mrf4 is not capable of establishing a robust myogenic population and MyoD-/;Myf-5-/- embryos are born largely devoid of skeletal muscle. Removal of either
MyoD or Myf-5 results in transient defects or delays in myogenesis, and
ultimately ends with a viable mouse with functional muscle (Braun et al., 1992;
Rudnicki et al., 1992). MyoD and Myf-5 may appear to have grossly overlapping
functions, evidenced by the single and double knock out phenotypes, but they
have differing genomic targets and specific functions during myogenesis. Real
time PCR expression data shows that MyoD is much more efficient at activating
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differentiation genes than Myf-5, while both proteins were shown to activate
growth phase target genes (Ishibashi et al., 2005).

Also, Myf-5-/- myoblasts

differentiate prematurely in vitro, at the expense of proliferation, (Montarras et al.,
2000) while MyoD-/- myoblasts divide quickly and differentiate poorly (Sabourin et
al., 1999). A more in depth review of MyoD function can be found in the following
sections.
Myogenin controls myogenic differentiation due to the fact that in
Myogenin knock out embryos, there are severe differentiation defects and
embryos die a birth, while myoblasts and primary myogenesis occurs normally
(Venuti et al., 1995). Historically, Mrf4 has been thought to be a differentiation
factor as Mrf4 null animals have normal muscle determination and differentiation,
but there is a four fold increase in Myogenin expression, likely a compensation
mechanism (Braun and Arnold, 1995). However, as stated above, Mrf4 can play
a role in myoblast formation.

1.3 MyoD; Structure and Function:

MyoD belongs to a subfamily of bHLH transcription factors involved in
myogenesis.

The bHLH family of transcription factors falls into two broad

categories. One is called Class I, and are broadly expressed in many cell types
and contain the E protein family.

Class II bHLH factors, that the MRFs are

members of, expression is restricted in a tissue specific manner. As mentioned
previously, forced MyoD expression in differentiated non muscle cells in vitro can
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be converted to muscle (Weintraub et al., 1989). For this to happen, genes must
be silenced, new genes activated, and chromatin remodeled. MyoD has the
ability to perform all of these functions and deserves a detailed description of its
structure, and more broadly the structure of bHLH transcription factors, and the
signaling pathways involving MyoD to describe its function.

1.3.1 Structure:

MyoD and the other MRFs share two domains with each other and with
other bHLH (basic helix-loop-helix) transcription factors, the DNA binding and
dimerization domains.

Variability among these factors lies in the presence,

absence, or combination of activation domains and repressive domains.

The

common element is comprised of approximately 60 amino acids containing the
DNA binding region (basic) followed by two alpha-helices, separated by a
variable loop region (HLH) (Ferre-D'Amare et al., 1993).

The HLH domain

allows for dimerization between two HLH containing factors, either through
homodimerization, which is uncommon, or through heterodimerization (Kadesch,
1993). Once dimerized, the basic regions of the two transcription factors bind
specific DNA sequences. During myogenesis, the MRF’s bind E-boxes, whose
consensus sequence is CANNTG, where N can be any nucleotide. MyoD has a
strong, single transcriptional activation domain at the amino terminal end and a
histine-cystine rich domain containing a tryptophan amino acid necessary for
interaction with the Pbx/Meis complex, a known transcriptional activator (Okada
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et al., 2003; Tapscott, 2005).

The strong transactivation domain of MyoD has

been used in a fusion protein with the DNA binding domain of Oct4 for a 50 fold
increase in production of induced pluripotent stem cells (iPSCs), partly due to the
chromatin remodeling ability of MyoD (Hirai et al., 2010).

1.3.2 Function:

MyoD is a master transcription factor that remodels chromatin and recruits
activating transcriptional complexes to the loci of many genes involved in all
aspects of myogenesis. MyoD does not perform all of its functions at once,
rather there is a temporal specificity to its actions, with some genes influenced
immediately, and others influenced within days of initiation of expression (Lin et
al., 1994; Zhao et al., 2002). MyoD has been shown to directly bind both early
and late genomic targets via CHiP data in a fibroblast cell line containing an
estrogen induced MyoD allele (Bergstrom et al., 2002). The proposed cause of
this phenomenon is a feed-forward mechanism, where early targets of MyoD are
needed to cooperate with MyoD to activate the next temporal level of genes
(Penn et al., 2004).

Acetylation of the MyoD protein has also been shown to

affect target gene selection (Di Padova et al., 2007).
The simplified description of MyoD function is that it heterodimerizes with
the structurally similar, but broadly expressed, E-proteins through their shared
HLH domains. Specifically, MyoD is shown to heterodimerize with E12 and E47
to activate myogenic genes, and this activation ability is at least partly governed
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by the MAP kinase p38 (Watada et al., 1995). p38 phosphorylates E47 at serine
140, and this modification is essential for association with MyoD (Lluis et al.,
2005). Then, through a combination of the lone activation domain of MyoD and
the variable activation/repression domains of the E-proteins, target genes are
activated or repressed. Strangely, the target DNA sequence of MyoD is short,
(CANNTG) and occurs frequently through out the mammalian genome. A large
amount of regulation via protein interactions are therefore required to obtain
target gene and temporal specificity. Specificity is achieved either by tandem E
boxes, or a combination of E boxes and binding sites for cooperative factors that
directly interact with the activation domain of MyoD, such as Mef2, Pbx, Meis,
and Sp1 (Knoepfler et al., 1999; Sartorelli et al., 1997; Sartorelli et al., 1990)
(Tapscott, 2005).
An essential family of transcription factors needed for activation of
essentially all myogenic genetic loci, is the MEF2 (myocyte enhancement factor)
family.

In mice, there are four members of the MEF2 family, and they are

required for the differentiation, but not specification of the myogenic lineage
(Black and Olson, 1998). Although MyoD and the MEF2 family bind different
consensus DNA sequences, both sequences are found at almost every skeletal
muscle genes promoter region, and efficient transcription of those genes only
occurs when both factors are bound (Dodou et al., 2003; Li and Capetanaki,
1994; Malik et al., 1995).
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1.3.2.1 Chromatin Modification and Remodeling:

Part of the temporal specificity in MyoD mediated myogenesis is due to
binding sites being hidden via inaccessible chromatin states. Many of the E-box
targets of MyoD and the other MRFs, are hidden by unfavorable chromatin at
time specific loci, or loci initially targeted at the onset of myogenesis. MyoD has
the ability to alter the epigenome of myogenic cells, by directly interacting with
the histone acetyltransferases (HATs), p300 and CBP (Bannister and Kouzarides,
1996; Ogryzko et al., 1996). Addition of acetyl groups to histone tails negates
their positive charge resulting in the weakening of their interaction with the
negatively charged DNA, allowing access to the DNA sequence.

The

MyoD/p300/CBP complex can recruit another HAT, p300/CBP-associated factor
(PCAF), resulting in a complex with two differing acetyltransferase abilities and
specificities (Puri et al., 1997; Sartorelli et al., 1997). p300 acetylates histone
proteins, weakening the protein-DNA interaction, allowing that region of DNA to
be accessible to transcription factors. PCAF acetylates the MyoD protein at two
lysine residues just outside of the DNA binding domain, increasing the
transcriptional activation ability of MyoD (Polesskaya et al., 2000) (Dilworth et al.,
2004).
Besides associating with histone modifying proteins, MyoD also recruits
protein complexes known to remodel chromatin.

The large ATP-dependent

SWI/SNF complex, actively moves histones or switches out nucleosome histone
subunits to facilitate transcription of previously silent local genes (de la Serna et
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al., 2005; Hirschhorn et al., 1992). The SWI/SNF complex directly interacts with
MyoD via the BAF60c subunit (Forcales, 2012).

1.3.2.2 Association with RNA Helicases:

MyoD has been shown to interact with two different RNA helicases, p68
and p72.

Generally, RNA helicases are enzymes that alter RNA structure and

are therefore involved in all aspects of RNA structure modification during
transcription, splicing, and translation (Abdelhaleem, 2004).

RNA helicases

mediate conversion between single stranded RNA and double stranded RNA,
and also affects the affinity of RNA for specific proteins. For a comprehensive
review, see (Jarmoskaite and Russell, 2011; Pan and Russell, 2010). The role of
RNA helicases involved in controlling cell determination or differentiation comes
from work showing a direct interaction between MyoD and p68 and p72. When
p68 and p72 are knocked down in HeLa cells or the immortal myoblast line,
C2C12, myogenic differentiation is severely diminished, such that multinucleated
myotubes never from in vitro and the cells fail to express myosin heavy chain, a
hallmark of differentiating skeletal muscle.

The proposed mechanism for the

inhibition of myogenic differentiation is through the lack of effective transcriptional
initiation complex formation at the promoters of myogenic genes, and also
through a failure of chromatin remodeling (Fuller-Pace and Ali, 2008).
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1.3.2.3 Transcriptional Repression by MyoD:

As a pioneer transcription factor, MyoD must remodel chromatin to access
target genes that are physically hidden, and then activate transcription of those
genes.

By virtue of MyoD’s ability to convert non-muscle cell types to the

myogenic lineage, it would be logical to assume that MyoD can repress genes
expressed in the cell type before myogenic conversion.
microRNAs (miRNA) are short, approximately 20 nucleotides in length,
single stranded RNAs that negatively impact gene expression by directing
degradation of specific mRNAs or inhibiting translation (Luo et al., 2013). Three
miRNAs, miR-1, 133, and 206 are all restricted to muscle cells and may be
controlled by the MRFs. MyoD has been shown to directly activate the
transcription of mIR-206, that suppress translation of transcripts expressed in
fibroblasts. Two genes expressed in fibroblasts, utrophin (Utrn) and follistatinlike 1 (Fstl1) have their mRNA reduced after the onset of MyoD expression due
to the fact that MyoD directly binds an E box near the genomic locus of miR-206.
The miR-206 locus is next to a gene activated by MyoD, AK132452, and mIR206 may be a result of processing of that gene. miR-206 then complementary
base pairs the 3’ UTR of

Fstl1 transcripts, targeting them for destruction

(Rosenberg et al., 2006). It is also suggested that MyoD activates transcription
of miR-133 and miR-1.

These miRNAs target the destruction of a histone

deacetylase, HDAC4, a transcriptional repressor, and serum response factor
(SRF), an anti-mitotic protein (Chen et al., 2006).
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The action of MyoD via

miRNAs promotes cell proliferation and gene expression at certain loci, while
repressing transcripts characteristic of non-myogenic lineages.
Another method of transcriptional repression via MyoD is through histone
deacetylase complexes (HDACs). MyoD recruits HDACs to genetic loci where
histones will be modified such that the genes close by will be repressed (Puri et
al., 2001). This phenomenon may be part of the temporal regulation of MyoD
target genes, as these repressive complexes are also seen at the Myogenin
promoter, a locus known to be activated by MyoD.

While a myoblast is

proliferating, some MyoD target genes will be activated at a later time, and need
to be temporarily repressed to avoid premature differentiation, and association
with HDACs is one pathway to achieve this effect.

1.4 Embryonic Myogenesis:

1.4.1 Somitogenesis:

During early embryogenesis, the neural tube and notochord lie at the
center of the embryo and define the anterior-posterior axis by their action as
signaling centers that induce surrounding tissues to adopt certain fates through
secreted factors and direct cell-cell interactions. On both sides of the neural tube
resides the paraxial mesoderm, a mesenchyme of multipotent cells that
eventually give rise to skeletal muscle, the axial skeleton, and the dermis of the
trunk.

Somites are epithelial spheres formed from segmentation of the paraxial
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mesoderm with a fixed periodicity starting at the anterior region of the embryo
and steadily progressing toward the posterior. Somites form with a fixed
periodicity governed by a ‘molecular clock’.

Many factors control the periodicity

of somite formation such as FGF8 (fibroblast growth factor 8) and Wnt3a
(Dubrulle et al., 2001) (Aulehla et al., 2003). Cycling expression of Notch family
members and their receptor components play an integral role in the
segmentation clock in all vertebrates (Gridley, 2006).

The morphological

boundary between each somite in mice is controlled by two bHLH transcription
factors, MesP2, regulated by Notch, and Paraxis (Sosic et al., 1997). If either of
these genes is removed from the mouse genome, the paraxial mesoderm fails to
undergo the mesenchymal to epithelial transition, and somites fail to form. These
mutations are lethal at birth due to fused vertebra and disorganized axial muscle.
Interestingly, the cell types found in a normal proper somite still form, but
segmentation and patterning are lethally incorrect.

MesP2 directly activates

Eph4A, a gene involved in cell-cell interaction, specifically cell-cell repulsion, an
action vital to somite formation (Burgess et al., 1996; Saga et al., 1997;
Takahashi et al., 2005). The initial somite is plastic in regards to what somitic
lineage it will become, as shown in somite rotation experiments (Dockter and
Ordahl, 2000).

Within a few hours of somite formation, the epithelial sphere

begins to change as lineage specification occurs.

The dorsal portion of the

somite maintains its epithelial nature and forms the dermomyotome, while the
ventral portion form the mesenchymal sclerotome (discussed below).
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The dermomyotome is a transient structure, where cells on the end of the
epithelial sheet delaminate, or lose their epithelial shape to become
mesenchymal. Factors secreted from the overlying ectoderm (Wnts1 and 7A)
(Tajbakhsh et al., 1998) induce myogenesis in dermomyotomal cells, while the
lateral plate mesoderm inhibits myogenesis in other cells types via BMP4. The
premyogenic cells activate MyoD or Myf-5 and migrate immediately medially to
populate the area under the dermomyotome, forming the myotome, the first
skeletal muscle of the embryo (Kalcheim et al., 1999). Subsequently, the
dermomyotome provides progenitor cells for all trunk and limb musculature. The
dermomyotome also produces trunk dermis, and limb endothelial cells (Kardon et
al., 2002a). The ventro-medial portion of the somite loses its epithelial nature to
return to a mesenchyme and becomes the sclerotome, and gives rise to the ribs,
vertebra, and tendons of the axial skeleton(Wilting et al., 1994).

This cell

structure conversion is controlled by Sonic Hedgehog (Shh), produced by the
notochord and floorplate of the neural tube by activating Pax1 in the future
sclerotome, and along with BMP4, the early formation of the axial skeleton
begins (Murtaugh et al., 1999).

1.4.2 Myogenic Lineages:

All skeletal muscle in the embryo is not formed through an identical
pathway.

At different anatomical locations in the body, there are differing
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environments and embryonic signaling centers regulating MRF expression. The
three major sites of skeletal muscle determination are the head, limbs and trunk.

1.4.2.1 Craniofacial Myogenesis:

Skeletal muscle of the head does not originate from somites, but from
unsegmented prechordal mesoderm located cranially to the first somite and from
the branchial arches. The branchial arches, a subset of the craniofacial muscle
population, are embryonic structures evolved from gill structures in fish, and in
mammals their derivatives still control feeding and breathing.

MyoD is

transcriptionally regulated differently in head muscles than in the body. In the
body, Myf-5 and Pax3 are genetically upstream of MyoD because in their
absence, MyoD is not expressed. In these mutant embryos, MyoD expression
occurs normally in the head and myogenesis occurs (Tajbakhsh et al., 1997). In
the absence of Myf-5 and MyoD, some trunk musculature forms due to Mrf4
expression, but Mrf4 is not expressed in the head and as a result, no myofibers
form in the head, demonstrating the differing upstream activators in the two
populations (Kassar-Duchossoy et al., 2004).
MyoR and Capsulin are bHLH factors related to the four major myogenic
bHLH transcription factors, and are expressed in migratory myogenic precursors
that travel from the unsegmented paraxial mesoderm to the branchial arches.
(Hacker and Guthrie, 1998; Noden, 1983; Noden et al., 1999) Specific head
muscles controlling mastication are missing in embryos missing functional MyoR
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(Msc or Musculin) and Capsulin (TCF21 or epicadian) genes.

MyoD and Myf-5

are not turned on in the first branchial arch in the absence MyoR and Capsulin
(Lu et al., 2002). Tbx1 and Pitx2 also regulate myogenesis in the branchial
arches due to resulting muscle defects when either gene is missing (Dong et al.,
2006; Kelly et al., 2004).

These phenotypes are restricted to the head,

supporting the fact that head and body myogenesis differ significantly.

1.4.2.2 Epaxial Myogenesis:

Muscle of the trunk and limbs arise from the dermomyotome of the
maturing somite and are broken down into two categories; epaxial and hypaxial
musculature. Epaxial muscle progenitors originate from the dorso-medial aspect
of the dermomyotome and form deep back muscles (Ordahl and Le Douarin,
1992), while hypaxial muscle precursors delaminate from the ventro-lateral
portion of the dermomyotome and give rise to ventral body wall muscle, and at
limb level somites, to the limb musculature(Christ B, 1977).
Formation of the early musculature in the embryo is a multiphase process.
Initially, a small group of cells at the dorso-medial lip of the dermomyotome,
closest to the neural tube, lose their epithelial nature, activate Myf-5 via Wnt1
and Shh (Cossu et al., 1996a), and migrate ventrally to create the primary
myotome. Timely myotome formation is dependent on Myf-5,as there is a one
day delay in myotome formation in Myf-5 null embryos(Arnold and Braun, 1996;
Braun et al., 1992). Pax3 is initially expressed throughout the somite, but its
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expression becomes limited to the dermomyotome. Ectopic Pax3 expression
can activate MyoD and Myf-5 in mesoderm and neural tube explants (Daston et
al., 1996; Williams and Ordahl, 1994). These early myotomal cells form the
pioneer fibers that become the scaffold for the new myogenic cells which begin to
arrive from all sides of the dermomyotome (Kahane et al., 2007). Ultimately, the
central dermomyotome breaks down and Pax3/7 expressing cells enter the
myotome directly.

1.4.2.3 Hypaxial Myogenesis:

The hypaxial lineage comprises abdominal wall muscles, the diaphragm,
and limb musculature (Kablar and Rudnicki, 2000). MyoD is activated in the
hypaxial domain of the dermomyotome via Wnt7a (Cossu et al., 1996b). MyoD
controls timely formation of hypaxial muscle lineages, as MyoD-/- embryos have a
one day delay in hypaxial myogenesis (Kablar et al., 2003). At inter limb levels,
the hypaxial myotome matures into intercostal and abdominal wall muscle. At
limb levels, a different phenomenon occurs where single cells are released from
the lateral portion of the dermomyotome, do not express any of the MRFs, and
migrate directly to the limb buds where they will activate the MRFs, proliferate
and eventually differentiate.
Many genes are known to control the delamination and migration of these
cells. Pax3 is arguably the most important gene as mutant mice lacking this
gene have no limb muscle, while trunk myogenesis is not affected (Bober et al.,
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1994).

Pax3 is positively regulated by Dach2, the vertebrate analog of the

Drosphila gene dachshund which is involved in the eye formation pathway
(Kardon et al., 2002b). Two members of a six member gene family are also
involved in proper migration of limb myogenic precursors are Six1 and Six4
(Grifone et al., 2005).

These two genes are genetically upstream of Pax3, as

are Eya1 and Eya2 (Grifone et al., 2007). If either the Eya gene pair or Six gene
pair is knocked out, Pax3 is not activated in the hypaxial dermomyotome,
resulting in a lack of limb musculature. Interestingly, the Six and Eya genes are
homologous to Drosophila genes that interact synergistically to control eye
development. In vertebrates, they still interact synergistically, but these specific
members control migration, while other members control other organ
development.
The lack of limb muscle phenotype in Pax3 mutants, or upstream
activator mutants, is due to a migration defect. Pax3 directly activates c-met,
(Yang et al., 1996) a transmembrane tyrosine kinase receptor located on the
cells that will migrate to the limb.

The ligand for this receptor is scatter

factor/hepatocyte growth factor (SF/HGF) and is produced by cells of the limb
bud (Bladt et al., 1995). Removal of the c-met gene causes limb myogenesis to
fail due to a lack of migration (Heymann et al., 1996) and ectopic activation of
SF/HGF causes delamination of cells from the dermomyotome of interlimb
somites, which normally do not produce lateral migratory precursors (BrandSaberi et al., 1996).

Pax7 and Lbx1 are also expressed in the migrating

population of premyogenic cells.

Lbx1 is another target of Pax3, as its
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expression is absent in Pax3 knockout embryos (Dietrich et al., 1998). Lbx1 is
only expressed in the lateral portion of the dermomyotome while cells are
delaminating and is turned off slightly after the cell arrives in the limb field. In
Lbx1 knock out embryos, cells delaminate but do not migrate properly.
Interestingly, there is a difference of phenotype between the forelimb and
hindlimb muscles. All hindlimb muscles are missing, while in the forelimb, only
the extensor muscles of the forearm muscle are missing, indicating that Lbx1
allows for cells to know their positional identity (Schafer and Braun, 1999). Two
other genes regulated by Pax3 in migratory precursors are Sp5 and CXCR4.
Sp5 is a transcription factor and vertebrate homologue of the Drosophila gene,
buttonhead. The function of Sp5 is unknown, and no phenotype is produced
when it is knocked out, but that may be due to the presence of seven other Sp
factors (Sahara et al., 2007) that may compensate for the lack of Sp5. CXCR4 is
a chemokine receptor whose ligand, Sdf1, is expressed in the limb mesenchyme.
In CXCR4 null mice, fewer progenitor cells reach the limb and there is an
increase in apoptosis (Vasyutina et al., 2005). Migratory cells also express Pitx2,
a factor involved in the organization of the muscle anlagen once the progenitors
reach the limb (Campbell et al., 2012).
There are numerous factors expressed in myogenic progenitor cells
before they leave the dermomyotome for the limb. These cells may already be
specified to myogenesis before arriving at the limb bud and activating the MRFs.
The data in this thesis suggests these migratory cells are largely determined to
myogenesis by factors present in the somite.
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1.5 Transcriptional control of MyoD expression:

Defining regulatory DNA elements of powerful transcription factors is of
ultimate importance in understanding transcriptional pathways and in designing
transgenic mouse lines. Enhancer mutations may result in ectopic or altered
expression of a gene and result in various pathologies depending on the specific
gene (Bastianutto et al., 2002; Fuhrmann et al., 1999; Majumdar and Diamandis,
1999).

It has been shown that MyoD-/- myoblasts serve as better transplant

material than wild type myoblasts in mice (Asakura et al., 2007) which may be
applicable to humans with muscle wasting diseases.
There are only two known enhancer elements positively controlling MyoD
expression. These elements, the Core Enhancer (CE) and Distal Regulatory
Region (DRR) lie 20kb and 5 kb upstream of MyoD, respectively. In in vitro
assays, these two enhancers exhibit activity in non-muscle cell types, contrasted
by the precise control of MyoD expression in muscle lineages in vivo (Goldhamer
et al., 1992). In a developing embryo, there are probably repressive signals
involved in MyoD expression. One method to hide these positively acting control
elements is the surrounding chromatin state.
Enhancers were identified with constructs containing various restriction
digest fragments of the 24 kb of human genomic sequence upstream of MyoD.
The fragments were ligated to the chlorampenicol acetyltransferase (CAT) gene
and stably transfected into various cell lines. The amount of enzymatic activity in
the cell lines represented the positive transcriptional ability of the DNA sequence
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in question. The most powerful fragment was F3, a 4kb segment containing the
258bp CE (Goldhamer et al., 1992). The CE and DRR share extremely high
sequence similarity and genomic position between human and mice (Asakura et
al., 1995; Goldhamer et al., 1995b). The highly conserved DRR maintains all
putative binding sites between the two species, which are four E-boxes
(CANNTG) and two MEF-2 sites (Chen et al., 2001). E-boxes are the DNA
elements which bHLH transcription factor family members bind to, while MEF-2
sites are bound by ‘myocyte enhancement factors’. This family of transcription
factors are calcium dependent transcription factors involved in cellular
differentiation and proliferation (McKinsey et al., 2002).

The sequence

similarities between the CE’s of humans and mice is approximately 90% and all
putative binding sites are maintained, including four E-boxes, an AP-1 site, and
a H4TF-1 site (Goldhamer et al., 1995b).
In the trunk, but not the limbs, Myf-5 lies genetically upstream of MyoD,
and Pax3;Myf-5 double mutants fail to activate MyoD at all in the body
(Tajbakhsh et al., 1997). As mentioned previously, Six1/4 are upstream of Pax3,
and in Six1/4;Myf-5 triple knockouts MyoD fails to activate as well (Relaix et al.,
2013). Another positive regulator of MyoD is SRF (serum response factor), and
when inhibited in myoblasts or differentiating myotubes, the MyoD locus is rapidly
shut down (Gauthier-Rouviere et al., 1996). Another group of interacting factors
is Sp1, YY1 and p300/CBP which are involved in chromatin remodeling
(L'Honore et al., 2003; Roth et al., 2003; Wilson and Rotwein, 2006). Cell-based
assays and in vitro studies show a partnership between Fox03, Pax3, and Pax7
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in the recruitment of RNA Polymerase II during the formation of the pre-initiation
complex at the MyoD locus in myoblast cultures. Fox03 is further implicated as a
direct activator of MyoD through Fox03 knock out experiments, where MyoD is
down regulated in regenerating muscle (Hu et al., 2008).
Recent findings regarding the transcriptional control of MyoD have shown
many factors bind the CE directly. Six1/4 regulates MyoD by binding the CE
(Relaix et al., 2013), as does CLOCK and BMAL1, regulators of the circadian
rhythm of MyoD expression (Zhang et al., 2011). A limb specific activator of
MyoD, Pitx2, has also been shown to bind the CE (L'Honore et al., 2010).
Repression of MyoD expression has also been linked to the CE as Sim2 and
YB1/p32 bind to the CE and repress the locus by both gain and loss of function
experiments (Havis et al., 2012; Song and Lee, 2010).
In vitro cell culture analysis shows the histone variant H3.3, associated
with transcriptionally active genes, is required to become associated with the CE
for proper expression of MyoD in myoblasts and differentiating myotubes (Yang
et al.), showing a role for epigenetic remodeling in the activation of the MyoD
locus via the CE.

1.5.1 Transgenic experiments:

Using upstream regions of MyoD to drive lacZ or CAT expression have
revealed two distinct elements, the Core Enhancer (Goldhamer et al., 1995a)
(CE) and the Distal Regulatory Region (DRR) (Asakura et al., 1995).
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24

kilobases of DNA sequence upstream of MyoD, containing the CE and DRR,
drives lacZ expression in a spatio-temporal pattern that fully mimics MyoD mRNA
expression.

Transgenic analysis indicates that the CE controls initiation of

expression in newly forming myoblasts, while the DRR maintains expression in
differentiating muscle. CE-lacZ transgenic embryos exhibit activity in a manner
similar to MyoD mRNA detection (Faerman et al., 1995; Goldhamer et al., 1992).
DRR-lacZ transgene expression is limited to sites of differentiating muscle
(Asakura et al., 1995). In MyoD-/-;Myf-5-/- embryos, where no myoblasts form, the
CE transgene is active while the DRR is not (Kablar et al., 1999) indicating the
ability of the CE to initiate de novo MyoD expression.

The 2.5 kilobases

immediately upstream of the transcriptional start site, including the proximal
promoter does not contribute to specificity of expression. The herpes simplex
virus promoter exhibited nearly identical activity in myoblasts as the native MyoD
promoter (Goldhamer et al., 1992). The genomic region upstream of MyoD that
had the highest activity was referred to as ‘fragment 3’ and contains the 258 base
pair long Core Enhancer (Goldhamer et al., 1992).

When comparing the

expression profile of the -24lacZ construct, which fully copies endogenous MyoD
expression, to a similar construct which lacks the F3 fragment, there is only a
delay in expression in the hypaxial myotome and limb buds up to E115, after
which a normal expression profile is regained (Chen et al., 2001).
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1.5.2 Deletion of Enhancers:

Given the data showing the sufficiency of the CE and DRR to regulate
MyoD expression, it is surprising to see these elements are not individually
necessary. In embryos lacking the CE, MyoD expression initiates properly in the
epaxial lineage while there is a 1 day delay of expression in the branchial arches
and limb buds (Chen and Goldhamer, 2004b).

This shows the initial timely

activation of MyoD is CE dependent in only a subset early myogenic cells, and
that ultimately, initiation of MyoD expression is CE independent.

Targeted

removal of the DRR resulted in persistent MyoD expression in differentiating
embryonic muscle, and this expression continues into adulthood, but with an
approximate 60% reduction in mRNA levels, showing continued MyoD
expression in differentiated muscle occurs without the DRR. DRR knock out
embryos exhibit a general reduction in MyoD levels at E10.5 (Chen et al., 2002).
The differences between transgenic and knock out experimental results can be
explained in two ways. The first is that the CE and DRR have overlapping or
compensatory abilities to regulate MyoD expression, such that when one is
removed, only transient or minor defects are observed, due to the presence of
the other enhancer. The second is that another, uncharacterized DNA regulatory
element exists. In this thesis, I resolve the two hypotheses by removing both the
CE and DRR on the same chromosome.

Here, targeting of the CE for deletion

was performed on mouse embryonic stem cells already lacking the DRR. The
expression profile of MyoD will be monitored in this new mouse line.
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Myf-5 initiates MyoD expression in the body, as there is a 2 day delay in
MyoD expression in Myf-5 mutants (Tajbakhsh et al., 1997). MyoD expression is
eventually rescued in Myf-5 mutants through a Pax3 dependent mechanism.
Delayed MyoD expression is also seen in mice lacking Myf-5 and the CE or DRR,
implying that both enhancers are responsive to Myf-5 dependent activation. The
kinetics of Pax3 dependent MyoD expression is the same in embryos with both
enhancers present or embryos lacking either the CE or the DRR (Chen et al.,
2002) (Chen and Goldhamer, 2004a) (Tajbakhsh et al., 1997), demonstrating
that neither the CE or DRR are exclusive targets of Pax3 dependent activation.
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Chapter 2: The MyoD expressing lineage remains multipotent in the trunk
but not the limbs of amyogenic embryos

2.1 Abstract:

Using the MyoDiCre/+;R26lacZ/+ genetic cell labeling system, we have for the
first time performed permanent lineage tracing of presumptive myoblasts in a
genetic background where no myoblasts or muscle fibers form. Recombined
cells persist until birth and in the trunk, labeled cells change their fate and
become cartilage, bone, and brown fat.

In the limbs, myogenic progenitors

migrate properly and pattern themselves in a manner similar to wild type
embryos.

Recombined limb cells do not express Pax7 or CD31 and only

contribute to the loose connective tissue found in the limbs of amyogenic
embryos.

The majority of these cells are surrounded by ER-TR7 positive

extracellular matrix and many recombined cells express Tcf4, a transcription
factor and fibroblast marker. The results suggest the MyoD expressing lineage
of presumptive trunk myoblasts can adopt alternate fates in the absence of
primary myogenesis while limb progenitors appear to be fibroblastic.
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2.2 Introduction:

MyoD is a pioneer transcription factor whose expression is restricted to
the skeletal muscle lineage. Forced MyoD expression from a retroviral vector in
hepatocytes, adipocytes, and fibroblasts, transforms them into muscle cells
(Weintraub et al., 1989) MyoD belongs to a highly conserved myogenic family of
basic helix-loop-helix (bHLH) transcription factors along with Mrf4 (Miner and
Wold, 1990), Myogenin (Wright et al., 1989) and Myf-5 (Braun et al., 1989).
These four factors are collectively referred to as the Myogenic Regulatory
Factors (MRFs).

MyoD and Myf-5 function earlier in skeletal muscle

development than Myogenin based on knock out experiments, while Mrf4 is
expressed throughout myogenesis (Kassar-Duchossoy et al., 2004).

Single

knock outs of either MyoD (Rudnicki et al., 1992) or Myf-5 (Braun et al., 1992)
result in mild, transient delays in muscle development, and animals are born with
skeletal muscle and are viable. Embryos lacking MyoD, Myf-5 and Mrf4 develop
no skeletal muscle, or their determined precursors, myoblasts (Rudnicki et al.,
1993) (Kablar et al., 2003) and the fate of these presumptive myoblasts is
investigated here.

Myogenin-/- embryos exhibit severe differentiation defects,

while myoblasts and primary myogenesis occurs normally (Venuti et al., 1995).
Mrf4 knock out embryos show normal muscle formation, but there is a four fold
increase in Myogenin expression (Braun and Arnold, 1995). Initially, myoblast
formation was thought to be controlled by MyoD and Myf-5 only, however, the
Myf-5 knockout allele, Myf-5Neo, transcriptionally silenced the nearby Mrf4 gene.
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The newer, Myf-5loxP allele allows for Mrf4 expression, and in MyoD-/-;Myf-5loxP/loxP
embryos, some skeletal muscle is produced, but not enough to support life as
embryos die at birth due to the absence of the diaphragm (Kassar-Duchossoy et
al., 2004). It has never been demonstrated that cells that activate the MyoD locus
in an amyogenic embryo can form other cell types, leaving the status of
presumptive myoblast determination in question.
All skeletal muscle of the trunk and limbs arise from somites, transient
embryonic structures flanking the neural tube. MyoD and Myf-5 are expressed in
a subset of somitic cells and form muscle, while the rest of the somite forms
dermis and the axial skeleton (Christ and Ordahl, 1995). MyoD and Myf-5 have
been shown to function as master transcription factors, activating numerous
muscle specific genes, but it has been proposed that myogenic progenitor cells
are indeed determined before the onset of MRF expression (Tajbakhsh et al.,
1997), specifically in the migratory precursors of the limb (Kablar et al., 1999b).
Myogenic progenitors of the limb arise from the somites at limb level, but
migrate directly to the limb bud without entering the myotome and without
expressing any MRF’s (Tajbakhsh and Buckingham, 1994).

Whether this

migratory cell population is determined in the somite without MRF expression, or
migrate in a multipotent state and are determined upon MRF activation by
signaling factor gradients present in the limb bud will be addressed. Support for
the view that migratory cells are determined in the somite includes selective limb
muscle group hypoplasia in mouse mutants lacking genes expressed in the
somite, ie; Lbx1 and the Six1/4 transcription factors, (Grifone et al., 2005) (Gross
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et al., 2000) (Brohmann et al., 2000) CXCR4 (Vasyutina et al., 2005) and Pitx2
(Campbell et al., 2012). Also, limb bud grafts at interlimb levels induce the local
somites to provide migratory cells to populate the ectopic limb muscle niche
(Hayashi and Ozawa, 1995). The dual population hypothesis is supported by
gene knockout experiments, where MyoD-/- embryos exhibit a delay in hypaxial
and limb myogenesis, while Myf-5-/- embryos have a delay in epaxial myogenesis
(Kablar et al., 1997). However, there is also data suggesting that premyogenic
cells are not determined, and migrate to the limb, where endothelial or myogenic
fates are determined by the signaling factors in the limb (Kardon et al., 2002a).
Our hypothesis is that multipotent cells of the somite become determined
to myogenesis upon MyoD or Myf-5 activation. To directly asses whether these
genes function as determination factors, MyoDCre/-;Myf-5Neo/Neo mouse embryos
containing a Cre-dependent reporter, will have cells that would have expressed
MyoD permanently labeled via Cre-dependent recombination. Recombination
results in heritable, continuous reporter gene production allowing for long term
lineage tracing. Contribution of labeled cells to other lineages show the cells of
the MyoD expressing lineage are not determined prior to MRF expression.
As described above MyoD-/-;Myf-5Neo/Neo embryos produce no myoblasts
(Rudnicki et al., 1993). The premyogenic population in these mice could have
died, or changed fate based on observations of brown fat expansion in the back,
and excess ‘amorphous loose connective tissue’ in the limbs of these double
mutants (Rudnicki et al., 1993) (Rot-Nikcevic et al., 2006).

Transgenic

experiments using Myf-5 regulatory regions to drive lacZ expression in
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amyogenic embryos showed that the Myf-5 expressing population could change
fate and contribute to cartilage of the axial skeleton.

Similar transgenic

experiments using MyoD regulatory regions to control lacZ expression show the
labeled population undergoing apoptosis, not contributing to other lineages, and
the eventual loss of lacZ detection by E13.5 (Kablar et al., 2003). Here, we show
recombined cells of the MyoD expressing lineage to contribute to the axial
skeleton

and

the

expanded

interscapular

brown

fat

in

MyoDCre/-;Myf-

5Neo/Neo;R26lacZ embryos and persist until birth, indicating that myogenic
progenitors with an active MyoD locus remain multipotent in the absence of
MyoD and Myf-5.
In contrast to the multipotent cells in the trunk, the limb population of
recombined cells is associated with no distinct structures. The premyogenic cells
migrate to the limb and pattern themselves into structures similar to muscle beds.
Recombined cells are found in the limb at birth, P0, and are only associated with
the connective tissue found in large quantities in the limbs. Immunofluorescent
detection of Pax7, an upstream factor of the MRF’s, is lacking in mutant limbs.
The recombined cells express Tcf4, a marker of fibroblastic cells (Mathew et al.,
2011), and are surrounded by a connective tissue extracellular matrix, that is
positive for ER-TR7 antibody reactivity. The fluorescent Cre dependent reporter,
R26EYFP, was used in conjunction with fluorescent detection of these proteins in
MyoDCre/-;Myf-5Neo/Neo;R26EYFP embryonic limbs.
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2.3 Materials and Methods:

Mouse breeding and genotyping

All mouse handling, breeding, and sacrificing were done in accordance
with our IACUC animal care protocol. All separate lines were maintained by
breeding to FVB mice. Experimental mice were generated by crossing
MyoDiCre/+;Myf-5Neo/+ males with MyoDNeo/+;Myf-5Neo/+;R26lacZ/lacZ (Jax# 003309) or
R26EFYP/EYFP females. The MyoDiCre allele was detected by PCR using a forward
primer (5′-GCGGATCCGAATTCGAAGTTCC-3′) that lies at the 3′ end of the
icre/+2pA

cassette and a reverse

primer in intron 1 of

MyoD (5′-

TGGGTCTCCAAAGCGACTCC-3′), generating a product of 149 bp. MyoDiCre
animals

were

bred

to

Myf-5Neo

(Jax#

002522)

These

males

were

MyoDiCre/+;Myf5Neo/+ males.

animals

bred

to

to

produce

MyoDNeo/+;Myf-

5Neo/+;R26lacZ/lacZ females in order to produce MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ
embryos with an estimated frequency of 1 in 16.

The MyoDNeo allele was

detected with the forward primer 5’- TGGATGTGGAATGTGTGCGAG-3’ and the
reverse primer 5’- TCACTGTAGTAGGCGGTGTCGTAG-3’ to create a 420 bp
product.

R26lacZ

was

detected

with

the

primers

5’-CCGAAATCCC

GAATCTCTATC-3' and 5’-TTGGCTTCATCCACCACATAC-3' to create a 333 bp
product.

The

R26EYFP

allele

GACGTAAACGGCCACAAGTT-3’
The

Myf-5Neo

allele

was

was

detected

and

5’-GGTCTTGTAGTTGCCGTCGT-3’.

detected
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using

using

the

the

primers

primers

5’-

5’-CGTTGG

CTACCCGTGATATT-3’ and 5’410

bp

product.

CAGCTCAGCTTTGTGTGCTC-3’ creating a

wild

type

allele

TGAAGGATGGACATGACGGAC-3'

and

reverse

Myf-5

used

forward

primer

5'-

5'-TGACCTTCTTCAGG

CGTCTACG-3' to create a 300bp product
All PCR reactions followed standard conditions and 30 cycles, with the following
annealing temperatures; MyoDiCre, Myf-5Neo, MyoDNeo, and R26EYFP at 57oC and
R26lacZ at 55oC.

X-Gal Staining

Embryos were collected in PBS and fixed in 2% paraformaldehyde/ 0.25%
glutaraldehyde/ in PBS pH 7.4 for 3 hours on ice, followed by several rinses in
PBS for 2 hours to overnight, all in individual screw cap tubes. Staining solution
was prepared in PBS and contained 2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6, 0.01% Tween, 0.1% sodium deoxycholate and 0.1% X-gal. The
staining solution was added to the embryos, and were placed in the dark at 37°C
overnight with gentle rocking. Following staining, embryos were washed in four
changes of PBS over several hours and stored in 1% paraformaldehyde at 4°C.

Paraffin Sectioning
X-Gal stained embryos were processed and paraffin embedded using
standard procedures, then serially sectioned at 10μm and counter stained with
Nuclear Fast Red (Vector labs)
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Cryostat sectioning

Embryos were isolated and fixed with 4% paraformaldehyde for 3.5 hours
at 4oC. The embryos were rinsed with cold PBS 4 times at 20 minutes each. The
fixed muscle was processed through a sucrose gradient of 15% sucrose in PBS
overnight, followed by 30% sucrose in PBS overnight. The processed tissue was
placed into OCT compound and quickly frozen in dry ice cooled isopentane. The
frozen tissue was cryosectioned at 10 microns and either stored at -80oC, or
immediately processed for observation.

Immunofluorescence

Slides for EYFP detection were blocked in PBSMT (2% powdered milk,
0.5% Tween in PBS) followed by rabbit anti-GFP antibody at a 1:500 dilution.
For Pax7 detection, slides underwent an antigen retrieval process of 6 minutes in
-20oC methanol followed by boiling sodium citrate for 30 minutes. Vector labs
Mouse on Mouse block was used according to manufacturers recommendations
(Vector # BMK-2202).

Pax7 supernatant (Developmental Studies Hybridoma

Bank) was applied 1:1 in PBMST overnight at 4oC. Tcf4 detection used only
boiling sodium citrate for antigen retrieval and a standard block (1% BSA, 10%
goat serum, 0.1% Tween in PBS). Rabbit anti-Tcf4 (Cell Signaling 2569P) was
applied at a 1:100 dilution in block, and incubated overnight at 4oC.

Perillipin

was detected using standard block, with the rabbit anti-perillipin (Sigma P1783)
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applied at a 1:500 dilution. ER-TR7 (Santa Cruz sc-73355) was detected using
standard block and a 1:400 dilution and incubated overnight at 4oC. Osterix was
detected using a standard 2 hour block (1% BSA, 10% goat serum, 0.1% Tween
in PBS) followed by an overnight incubation of the primary antibody, rabbit antiosterix (abcam# ab22552), at a 1:250 dilution. The surface antigen, CD34, was
detected using standard conditions with a 2 hour primary incubation, using ratanti CD34 (abcam# ab8185)at a 1:200 dilution.
Secondary antibodies were used at a 1:500 and dilution and are goat antirabbit Alexafluor 488 (GFP) ( Invitrogen A11008), goat anti rat 568 (ER-TR7)
(Invitrogen A11077) and for all other applications, goat anti rabbit 555 ( Invitrogen
A21428)
.
Imaging

Whole mount images were taken using a Lecia MZ FLIII and sections were
viewed using a Nikon Eclipse E600. Images were captured using a Spot 25.2 2
Mp Color Mosaic camera using Spot Software V4.6 by Diagnostic Instruments.
Images were modified using Photoshop CS2.

42

2.4 Results:

2.4.1 Time Course of Cell Labeling During late Embryogenesis

MyoDiCre/Neo;Myf-5Neo/Neo embryos, referred to as 'mutant' for brevity,
harboring a Cre-dependent reporter, were collected from E13.5 until birth,
postnatal day zero, or P0. E13.5 is the chosen starting point as it's when cells
were 'lost' in previous experiments using lacZ transgenes for lineage tracing
(Kablar et al., 2003).

Using a Cre-dependent reporter, we are able to

permanently label any cell that has activated the MyoD locus, and this label is
passed on to all daughter cells. The Cre-dependent reporter, R26lacZ, was used
for most developmental stages, while R26EYFP was used for the P0 time point due
to a lack of reagent penetration during X-Gal staining and for the ease of
fluorescent immunological detection of cell specific markers in conjunction with a
fluorescent reporter. Both reporter constructs are identical except for the reporter
gene that gets activated following Cre mediated recombination. E13.5 mutant
embryos show a massive decrease in lacZ positive cells compared to
phenotypically wild type embryos (Figure 2-1). This result can be expected when
no myoblasts form, causing a lack of cell proliferation and fusion into muscle
fibers.

However, a relatively large number of β-Gal positive cells persist in

embryos lacking all primary MRF activity in both the epaxial and hypaxial
domains.

43

Recombined cells in the developing cranial region were largely ignored in
this analysis due to the many differences known to exist between head and body
myogenesis, resulting in difficulties in interpretation of the results. These
differences include head muscle progenitors arising from prechordal mesoderm,
not from somites, unique regulation of MyoD (Tajbakhsh et al., 1997), and other
distinct factors that drive myogenesis solely in the head, such as MyoR, Pitx2,
Tbx1, and Capsulin (Lu et al., 2002) (Noden and Francis-West, 2006) (Grifone
and Kelly, 2007).
Embryos collected at E14.5, 15.5, 18.5, and newborns, denoted P0, show
that recombined cells persist (Figure 2-2 A and B), and do so until E18.5 (Figure
2-2 C).

P0 embryos contain the enhanced yellow fluorescent protein gene,

EYFP as a readout of Cre-dependent recombination. Due to the size of newborn
mice, and low fluorescent levels of EYFP, whole mount images are not
informative and have been omitted. Identification of cell position and cell type
marker expression in the newborn mice is achieved by cryosectioning and
immunofluorescent antibody detection. MyoD is a lineage specific marker, and
finding cells that normally would have expressed MyoD changing their fates and
not undergoing apoptosis, provides firm evidence that the MyoD expressing
lineage of presumptive myoblasts remains multipotent in the amyogenic embryo.
We have shown that presumptive myogenic cells persist and do not
apoptose in the absence of MRFs. Previous lineage tracing experiments (Kablar
et al., 1997; Kablar et al., 1999a) were inconclusive because reporter gene
expression was only temporary, and the absence of labeled cells meant either
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the transgene was silenced, or the cells died. Using a permanent cell labeling
system, we now know the absence of signal was due to transcriptional silencing
of the reporter transgene.
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Figure 2-1

MyoDiCre/+;R26lacZ

MyoDiCre/-;Myf-5-/-;R26lacZ

B

A
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Figure 2-1. X-Gal staining in E13.5 wild type and mutant embryos

Observation of labeled myoblasts and muscle fibers in phenotypicaly normal
MyoDiCre/+;R26lacZ embryos (A) and cells that have activated the MyoD locus in
MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos (B). There is a marked decrease of
recombined cells in the mutant, particularly in the trunk. Branchial arch derived
myogenic progenitors activate the MyoD locus and remain in large numbers in
the mutant (yellow arrows). Labeled cells in the limbs of mutants maintain a
physical pattern reminiscent of wild type in the fore (red arrows) and hind limbs
(green arrows).
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Figure 2-2

E13.5
A

E14.5

E18.5
C

B
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Figure 2-2. Time course of recombined cell staining during late embryonic
and fetal development in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ mice

Labeled cells persist through E18.5 in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos.
Limb staining shows a clear progression of recombined cell patterning from one
developmental stage to the next (red arrows). Quantity and patterning of labeled
cells was consistent between embryos at similar developmental time points.
Recombined cells in the trunk are difficult to see due to their low number and
density.
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2.4.2

Fate

changes

in

recombined

cells

in

the

trunk

of

E13.5

MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos

In the absence of the primary MRF's, recombined cells contribute to
cartilage in the forming scapula (Figure 2-4 A, red arrow) and vertebra (Figure 24 B red arrow) and are histologically identical to their non recombined neighbors.
While many labeled cells contribute to the endochondral ossification process,
many more remain as loose connective tissue, found in place of skeletal muscle
surrounding the bones (Figure 2-4 A and B, black arrows). In MyoDiCre/+;R26lacZ
embryos, recombined cells contribute only to skeletal muscle, and their precursor
myoblasts.
Interscapular brown fat pads, a major source for non-shivering
thermogenesis in neonates, from both mutant and wild type embryos were
isolated and sectioned. A large number of recombined cells are found in the fat
pads

of

mutant

embryos

(Figure

2-4

C)

and

indistinguishable from their non-recombined neighbors.

appear

histologically

Interestingly, in the

dorsal portion of the trunk, there is a large amount of fluid underneath the skin,
making it prone to tearing. Sectioning embryos shows empty pockets where
cells are absent.

No recombined cells were found in the fat pads of

MyoDiCre/+;R26lacZ embryos.
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Figure 2-3

MyoDiCre/+;R26lacZ MyoDiCre/-;Myf-5-/-;R26lacZ
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Figure 2-3. Recombined cell patterning in forelimbs

10 μm transverse paraffin sections of limbs in E13.5 mutant (B) and wild type (A)
embryos. In A, migratory myogenic precursors populate the limbs and pattern
themselves into developing muscle beds. In B, recombined cells do not undergo
myogenesis, but position themselves in a manner similar to myoblasts. Red
arrows indicate the medial portion of the limb, while black arrows indicate the
lateral portion. The distal portion of the limb is located at the bottom of the image.
Nuclear fast red used as counter stain.
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2.4.3 Limb Phenotype in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos

Myogenic progenitors of the limb in MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ
embryos not only migrate from limb level somites properly, they also pattern
themselves in a manner similar to wild type embryos (Fig 2-3), and these cells
persist past E18.5 (Figure 2-2 C) until birth (Figure 2-10 B and E). The limb
patterning results are reproducible at each stage, indicating precise activation of
the MyoD locus in the limbs. It has previously been shown that cells migrate to
the limb prior to MRF expression, so this result is not surprising. The fact that
these cells persist, and continue to maintain a reproducible pattern until birth is
novel. Labeled cells do not contribute to any identifiable structures in the limb,
such as bone and skin.
The amyogenic phenotype has been reported in other studies, but
descriptions of the limb have been lacking.

With no muscle in the limb,

fibroblasts proliferate and make up almost the entire volume of the limb. These
delicate, fibrous cells are not durable and prone to damage during skinning,
embryo manipulation. During sectioning, the delicate nature of the tissue causes
section tearing. It is possible to see the bones of the limb through this delicate
tissue (Fig 2-7B red arrows). Quality sectioning of embryos is difficult due to the
lack of a strong cellular structure. In the forelimbs, the radius and ulna are much
closer together in mutant versus wild type embryos (Fig 2-8), as are the tibia and
fibula in the hindlimbs.
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Figure 2-4
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Interscapular Brown Fat

Figure 2-4. Labeled cells contribute to non myogenic lineages in the trunk

10 μm paraffin cross sections of E13.5 MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ embryos.
The cartilage condensations of the developing scapula (A) and vertebra (B)
contain lacZ+ cells only in MyoDiCre/Neo;Myf-5 Neo/Neo;R26lacZ embryos (red arrows).
Recombined cells also populate the area surrounding the developing bone (black
arrows). Labeled cells are also present in the interscapular brown fat pads from
E13.5 to birth (C).
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MyoDiCre/-;Myf-5-/-;R26EYFP
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Phase

G

E EYFP

Figure 2-5. Recombined cells in the trunk contribute to bone at P0

Serial 10μm cryosections of MyoDiCre/Neo;Myf-5Neo/Neo;R26EYFP embryo (A-D and
H-M). Panels A-D show Osterix positive bone cells (red) of the rib rudiments.
Phase contrast image (A) is characteristic of bone morphology in phase panels G,
J, and M. Dapi (C, E, H, K) was used to visualize nuclei.
show EYFP+ cells in different rib rudiments.

Panels F, I, and L

Panels E-G are from a

MyoDiCre/+;R26EYFP embryos and show no EYFP detection in bone, only in the
surrounding muscle. Scale bars represent 30 μm.
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Figure 2-6
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Figure

2-6.

Recombined

cells

contribute

to

brown

fat

in

P0

MyoDiCre/Neo;Myf-5Neo/Neo;R26EYFP animals

10 μm serial cryosections of MyoDiCre/+;R26EYFP (A and B) and MyoDiCre/Neo;Myf5Neo/Neo;R26EYFP newborns(C and D). Perilipin (red in A and C), a fat specific
marker, was used along with section location to identify interscapular brown fat
pads. In serial sections from MyoDiCre/Neo;Myf-5-/-;R26EYFP embryos, EYFP+ cells
contribute to perilipin positive brown fat (C). Dapi used to visualize nuclei. Scale
bar represents 30 μm.
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2.4.4 Fate of recombined cells in the trunk and limbs at P0 in
MyoDiCre/Neo;Myf-5Neo-Neo;R26EYFP embryos

There are differing results in the fate of labeled cells in the trunk versus
the limbs in mutant embryos. In the trunk, fate changes take place, and cells that
would normally form muscle express perillipin and contribute to brown fat (Fig 26), while others are osterix positive and contribute to bone (Fig 2-5). Due to the
low level of EYFP expression, antibody detection is used to enhance the signal.
Serial cryosections were used for antibody detection of other markers.
In the limb, labeled cells do not contribute to bone or vasculature, and
instead, the vast majority remain clustered in a 'rod' aligned along the proximaldistal axis (Fig 2-7) with some recombined cells remaining outside of the rod.
Some EYFP positive cells express Tcf4, a fibroblastic marker (Mathew et al.,
2011), and are surrounded by an ER-TR7 (Van Vliet et al., 1986) positive extra
cellular matrix (Fig 2-9). It can be safely assumed that these cells have become
fibroblastic or are stalled in their developmental pathway.
Not all of the EYFP+ cells express Tcf4, so if some of our cells of interest
remain poised for myogenesis, they should express the early myogenic marker,
Pax7 (Halevy et al., 2004).

However, no Pax7 positive cells were found in

mutant limbs, either in the EYFP positive or negative areas (Fig 2-10 E and F).
In wild type limbs, Pax7 is expressed in satellite cells, the tissue specific stem
cell used in muscle growth and repair (Fig 2-10 A and B).
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While no EYFP+ cells were found in the bones of the limb, and some
EYFP+ cells are phenotypically fibroblastic, we investigated whether recombined
cells could contribute to endothelial vascular cells, the other major limb cell type
present. In the mutant limbs, there is a severe reduction in the amount of CD31+
vasculature (Fig 2-10 G and H) in comparison to wild type (Fig 2-10 C and D). Of
the rare CD31+ cells found in the mutant, none of them were EYFP+.
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Figure 2-7
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Figure 2-7. Forelimb close up of E18.5

MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ

embryo

Limbs contain no muscle fibers and are largely transparent, allowing visualization
of limb bones (red arrows show radius and ulna in B).

(B) is a higher

magnification image of the limb in (A). Loose connective tissue comprises the
majority of soft tissue in the limb and is quite fragile. In (A), the green arrow
indicated the distal paw, while red arrow points to proximal elbow.
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MyoDiCre/-;Myf-5-/-;R26lacZ
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Figure 2-8
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Figure 2-8. Paraffin sections of E18.5 forelimbs

10 μm paraffin sections of MyoDiCre/+;R26lacZ (A) and MyoDiCre/Neo;Myf5Neo/Neo;R26lacZ (B) E18.5 forelimbs. The distance between the radius and ulna is
smaller in B compared to A. In both panels, blue cells have historically activated
the MyoD locus. The thick 'rod' of cells seen in Figure 2-7 is shown in cross
section (in B, red circle). Other, less concentrated, β-Gal positive cells are also
seen in B (red arrows).
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Figure 2-9
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Figure 2-9. Fibroblastic recombined cells in P0 limb sections

EYFP+ cells in the limb of MyoDiCre/+;R26lacZ embryo cryosections (A-D) show
EYFP+

skeletal

muscle

and

position

of

fibroblasts.

MyoDiCre/Neo;Myf-

5Neo/Neo;R26EYFP embryos (E-H) show the dense packing of cells seen in Figures
2-7 and 2-8. In serial sections, EYFP+ areas are surrounded by the extracellular
matrix protein, ER-TR7 (H) and some cells express the fibroblastic marker Tcf4
(G). Scale bar represents 30 μm.
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Figure 2-10
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CD31
D

H

Figure 2-10. Recombined cells in mutant embryos do not express Pax7 or
CD31 at P0

Pax7, a marker of pre and early myogenic cells, is found only in
MyoDiCre/+;R26EYFP

sections (A and B) and nowhere in MyoDiCre/-;Myf-

5Neo/Neo;R26EYFP sections (E and F). CD31, an endothelial cell marker, is greatly
reduced in mutant (G and H) versus control (C and D) limb sections. Also, no
EYFP+ cells in the mutant were CD31+. Scale bar represents 30 μm.
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2.5 Discussion:

MyoD is such a potent transcription factor that its trans-activation domain
has been fused to other DNA binding domains in order to increase the efficiency
of forming iPS cells (Hirai et al., 2012) and cardiomyocytes (Hirai et al., 2013) in
culture.

MyoD has incredible chromatin remodeling abilities and activates

transcription at many downstream loci.

MyoD directly recruits the SWI/SNF

chromatin remodeling complex to specific sites(de la Serna et al., 2005), leading
to muscle specific E box binding (an excellent review (Tapscott, 2005)).
However, there has been no classical experimental evidence proving
MyoD is a determination factor. To prove a cell is determined, transplantation of
the cells in question to an ectopic site in the embryo is performed.

If the

transplanted cells maintain their original identity, they were determined to a fate
at the time of transplant.

Myoblast transplants in mice to ectopic sites form

skeletal muscle, but myoblasts have already expressed MyoD, and the results
are not informative (Irintchev et al., 1998). Somite rotation experiments in the
developing chicken embryo show that cells of the somite are plastic in newly
formed somites, as well as the two sets located cranially (Dockter and Ordahl,
2000). Some of the cells in the somite have already expressed Myf-5, but not
MyoD, at the time of rotation, but early in somite maturation, appropriate gene
expression requires continuous exposure to signaling centers in the embryo
(Pownall et al., 2002).
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The questions addressed here are if the MyoD expressing lineage
remains multipotent in the absence of myogenesis and if the lineage remains
multipotent in epaxial (trunk) and hypaxial (limb) myogenic fields.

Given the

complex, and still largely unknown, upstream activators of MyoD, cells may be
determined by one or more upstream factors before the onset of MyoD
expression and myogenesis.

Here, we analyzed the fate of cells that have

activated the MyoD locus, in the absence of MyoD and the other primary MRFs,
while all upstream signaling pathways are unperturbed.
Previous lineage tracing studies using transgenes have only followed Myf5lacZ+ cells through E15.5, and MyoDlacZ+ cells to E13.5 in amyogenic
embryos (Kablar et al., 2003; Kablar et al., 1999a). The conclusion from these
reports, along with an increase in the number of apoptotic cells, was that cells of
the MyoD lineage apoptose and do not contribute to other lineages, while cells in
the Myf-5 lineage remain and contribute to other cell lineages, such as cartilage.
Using Cre recombinase we show the MyoD lineage persists and the loss of
signal was due to transcriptional silencing of the transgene. Our current findings
demonstrate that myogenic progenitors in the trunk abandon myogenesis before
E13.5, and instead are able to progress down different lineages, such as
cartilage, bone, and brown fat. In the limbs, our labeled population survives and
contributes only to the fibroblastic-like cells of the limbs.
A common hypothesis was that MyoD and Myf-5 control myogenesis in
two different cell lineages as opposed to single cells expressing both factors.
Recent supporting experiments used diphtheria toxin (DTA) driven lineage
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ablation, to kill Myf-5 expressing cells, yet skeletal muscle still forms (Haldar et
al., 2008) demonstrating that a Myf-5 independent lineage exists.

However,

when the MyoD expressing lineage is ablated, no muscle remains in embryos at
E18.5 (preliminary data in chapter 4) (Wood et al., 2013). Also, it has been
shown that all satellite cells, muscle specific stem cells, express MyoD prenatally
(Kanisicak et al., 2009). Taken together, these results show that all cells in the
myogenic lineage express MyoD, while not every cells expresses Myf-5. This
means that the fate changes seen in Myf-5lacZ amyogenic embryos are
accounted for in this study. Our results show that cells that have activated the
MyoD locus persist until birth, and take on different fates.
There are differing observations of cell fate plasticity in trunk versus limb
myogenic progenitor cells. These two populations are quite different, as trunk
myogenesis begins earlier and limb progenitors migrate directly from the
dermomyotome, without entering the myotome.

Cells that populate the limb

express several genes that trunk progenitors do not, such as c-met and Lbx1
(Mennerich and Braun, 2001). Expression of the transcription factors Pax3,
Pitx2, Dach2, Eya2, and Six1/4 remains only in the hypaxial edge of the
dermomyotome and in migratory limb progenitors (Grifone et al., 2007; Heanue
et al., 1999; Kardon et al., 2002b; L'Honore et al., 2010). These migratory cells
don't express any MRFs until they reach the limb field. As they are the only
source of skeletal muscle for the limbs, they are possibly already specified for the
myogenic fate as they leave the somite. Trunk myoblasts and bone progenitors
share a common somitic origin, while the bones of the limb derive from lateral
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plate mesoderm.

This may explain the inability of recombined limb cells to

contribute to osteogenesis. The other fate change, recombined brown fat cells,
may be linked to a common origin as well. Prdm16 has been shown to control a
switch between skeletal muscle and brown fat fate decisions, such that over
expression of Prdm16 can convert myoblasts to brown fat (Seale et al., 2008).
Brown fat progenitors have been shown to activate the Myf-5 locus (Shan et al.,
2013), and MyoD;Igf2 double null animals have an increase in brown fat
development (Borensztein et al., 2012).

However, limb myogenic progenitors

share a dermomyotomal origin with limb endothelial cells, but there was no fate
change noted.

This may be due to specification in the somite followed by

signaling molecules in the limb regulating fate decisions (Kardon et al., 2002a).
As previously stated, the MyoDiCre labeling system labels the entire
embryonic population of myoblasts, while Myf-5Cre does not. While this project
was underway, this fact was not yet known.

Therefore, MyoDiCre/Neo;R26lacZ

embryos were analyzed for any fate changes in the absence of MyoD only, as
MyoD and Myf-5 might control myogenesis in two different cell lineages. All
recombined cells contributed to muscle in these embryos, and the data was
excluded. In retrospect, if the DTA experiments reflect the actual biology, then
some premyogenic cells do not express Myf-5, and are dependent on MyoD or
Mrf4 for access to the myogenic program. In MyoDiCre/Neo;R26lacZ embryos, MyoD
expressing cells do not contribute to other fates, perhaps due expression of Myf5 and Mrf4. If there is a MyoD dependent myogenic lineage, its close proximity
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to Myf-5 and Mrf4 expressing myogenic cells may lead to fusion into the forming
muscle fibers.
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Chapter 3: Embryonic transcriptional regulation of MyoD is largely
independent of the Core Enhancer and Distal Regulatory Region

3.1 Abstract:

Transgenic experiments identified two enhancers of the muscle specific
gene, MyoD.

These enhancers, called the core enhancer (CE) and distal

regulatory region (DRR), control the initiation and maintenance of expression,
respectfully. However, deletion of CE results in only a mild expression delays in
the limb buds and branchial arches, while deletion of the DRR results in lowered
postnatal expression levels.

Here, we have removed both enhancers via

homologous recombination to address the functional redundancy between the
two enhancers.

In homozygous embryos with both enhancers removed

(MyoDΔCEDRR/ΔCEDRR),

MyoD expression continues with a one day delay in

hypaxial lineage expression, reminiscent of CEloxP/loxP embryos who only lack the
CE (Chen and Goldhamer, 2004a). An even milder delay in early myotome
expression is the only novel phenotype in MyoDΔCEDRR/ΔCEDRR embryos.

In

additon, the removal of the 15 kb of DNA between the CE and DRR,
(MyoDΔCE15DRR/ΔCE15DRR) resulted in identical expression kinetics. In the absence
of Myf-5, MyoD expression is dependent on Pax3. The rescue kinetics in these
new lines are identical to wild type embryos.

Ultimately, the CE and DRR are

not necessary for largely normal MyoD expression.
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In an attempt to identify the new enhancers, a genomic approach was
taken to analyze 2 Mbp surrounding MyoD for conserved sequences across
species and for transcriptionally positive epigenetic markers.

We found the

introns of MyoD contain positive epigenetic marks, are conserved across species,
and have putative binding sites for several transcription factors.

3.2 Introduction:

MyoD is a pioneer transcription factor that activates genes necessary for
myogenesis in a temporally regulated manner, remodels chromatin, promotes
proliferation and orchestrates a complex cellular response. Two excellent reviews
can be found here (Tapscott et al. 2005, Singh et al. 2013).
MyoD is one of four members of the myogenic family of bHLH
transcription factors that control embryonic and postnatal myogenesis. Myoblast
formation is controlled by MyoD and Myf-5, and to a lesser extent Mrf4, while
myogenic differentiation and fiber formation is performed primarily by Mrf4 and
Myogenin. In the original MyoD-/-;Myf-5-/- embryos, myoblasts fail to form and
myogenesis fails (Rudnicki et al., 1993). However, this phenotype was partly due
to transcriptional silencing of the Mrf4 locus by the Myf-5Neo allele. When a
different Myf-5 knockout allele is used, Myf-5loxp, Mrf4 expression is not
compromised and some Myosin Heavy Chain positive cells form, but myogenesis
is not robust enough to produce viable animals (Kassar-Duchossoy et al., 2004).

79

In order to understand the transcriptional regulation of MyoD, we must
define it's enhancer regions. Enhancer mutations can result in ectopic or altered
gene expression that results in various pathologies depending on the specific
gene of interest (Sur et al., 2012) and reviewed (Pennacchio et al., 2013). It has
been shown that MyoD-/- myoblasts serve as better transplant material in mice
than wild type myoblasts (Asakura et al. 2007) and this finding may be applicable
to humans with muscle wasting diseases.

If MyoD can be temporarily

transcriptionally repressed during in vitro culture and expansion of patients
myoblasts, a useful number of cells can be generated for transplant.
Early knowledge of the upstream transcriptional regulators of MyoD
expression comes from gross embryonic disruption of signaling centers, such as
the notochord, neural tube, and surface ectoderm, impacting BMP, Shh and Wnt
signaling pathways. (Reviewed by (Borycki and Emerson, 2000)). Removal of
the neural tube from avian embryos causes MyoD expression to end, possibly
due to a lack of Wnt signaling (Bober et al., 1994a). Members of the Wnt family
of transcriptional activators are expressed in the neural tube, Wnt1 (Tajbakhsh et
al., 1998), and surface ectoderm, Wnt7a (Cossu et al., 1996), and these two Wnt
factors are shown to activate myogenesis in mesodermal cells. Sonic Hedgehog
(Shh) is expressed in both the notochord and floorplate of the neural tube and
has been shown to be promote myogenesis, while Shh-/- embryos exhibit
myogenic defects (Marcelle et al., 1999). However, there has been no evidence
of direct binding of these factors to the MyoD locus. The Wnt and Shh pathways
may indirectly control MyoD expression.
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To define the cis-acting DNA elements directing MyoD expression,
transgenic experiments using human sequence of the upstream regions of MyoD
to drive lacZ or CAT (chloramphenicol acetyltransferase) expression were
performed. A transgene containing 24 kb of DNA upstream of the human MyoD
gene was fused to the CAT gene and its transcriptional activity was tested in
23A2 myoblasts (Goldhamer et al., 1992). CAT was expressed at high levels,
and the construct was reduced to smaller fragments to isolate discrete enhancers.
A 4 kb portion called Fragment 3 (F3), lying 22 to 18 kb upstream of MyoD,
directs reporter gene expression almost identically to the entire 24 kb construct.
Removal of F3 from the original construct created -24ΔF3CAT, and expression
levels dropped to baseline levels (Chen et al., 2001). -24lacZ and -24ΔF3lacZ
constructs containing human DNA were also used to generate transgenic mouse
embryos for in vivo analysis.

-24lacZ embryos exhibited reporter gene

expression in mouse embryos in a pattern that fully mimics endogenous MyoD
mRNA expression (Goldhamer et al., 1992). -24ΔF3lacZ embryos exhibit delays
and reduction of reporter expression at all myogenic locations (Chen et al., 2001)
while F3lacZ constructs direct reporter gene expression in a manner faithful to
MyoD mRNA in mouse embryos (Faerman et al., 1995). At the center of F3 is a
258bp element, the core enhancer (CE), largely responsible for the
transcriptional activity of F3 (Goldhamer et al., 1995).

Similar experiments

identified a second enhancer, the distal regulatory region (DRR), 4kb 5' to MyoD
(Asakura et al., 1995). The CE and DRR share sequence homology between
mice and humans, explaining how human noncoding regions are capable of
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driving proper expression in mouse embryos. The DRR is 71% identical, and all
putative binding sites are preserved (Chen et al., 2001). Mutation of the YY1 and
SRF binding sites in the DRR eliminates its enhancer activity in vitro (L'Honore et
al., 2003). The CE is 87% identical and also maintains binding sites across
species (Goldhamer et al., 1995). Transgenic analysis indicates that the CE
controls initiation of expression in newly forming myoblasts, while the DRR
maintains expression in differentiating muscle. In support of this idea, in MyoD-/;Myf-5-/- embryos, where no myoblasts form, the CE transgene is active while the
DRR is not (Kablar et al., 1999). The drawbacks to these transgenic experiments
are that the genomic regions of interest are assayed outside of their normal
chromosomal context, and the results show only the sufficiency of these DNA
elements in driving transcription of the reporter gene.
The necessity of the CE and DRR has been investigated by deletion of
either enhancer from the mouse genome. Deletion of the CE resulted in MyoD
expression initiating properly in the myotomes, while a 1 day delay of expression
was observed in a subset of the hypaxial lineage, specifically the limb buds and
branchial arches (Chen and Goldhamer, 2004b).

This shows the CE is not

necessary for initial activation of MyoD and that the CE controls timely activation
in only a subset of myogenic cells. Targeted removal of the DRR resulted in a
decrease of MyoD expression at E10 only. In adult muscle, MyoD expression
continues, but with an approximate 60% reduction in mRNA levels, showing
continued MyoD expression in differentiated muscle occurs without the DRR,
albeit at reduced levels (Chen et al., 2002).
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In summary, 24 kb of human DNA sequence upstream of MyoD can drive
high levels of reporter gene expression in myoblasts in vitro and in developing
mouse embryos. The same is true for CE and DRR driven transgenes as well.
However, when the mouse equivalent of either of these enhancers are deleted,
only mild changes in MyoD expression are seen.

In -24ΔF3lacZ embryos,

reporter gene expression shows a much more severe delay in limb expression
than does MyoD expression in embryos lacking only the CE. Interestingly, there
is no delay in branchial arch expression in -24ΔF3lacZ embryos, unlike embryos
lacking the CE. These somewhat contradictory findings along with the difference
between necessity and sufficiency of these enhancers regions may lie in the
species difference between the transgenic and knock out experiments. Another
possibility is that in the mouse, the CE and DRR have overlapping or
compensatory abilities to regulate MyoD expression. The last possibility is that
one or more uncharacterized DNA regulatory element exists. The best way to
resolve the last two hypotheses is to remove both the CE and DRR on the same
chromosome.

In this chapter, targeted deletion of the CE was performed in

mouse embryonic stem cells lacking the DRR.
A finer point of MyoD regulation investigated is the target of Pax3
dependent rescue of MyoD expression. MyoD expression in the body is initially
Myf-5 dependent, and there is a delay in MyoD expression in Myf-5 knock out
embryos (Tajbakhsh et al. 1997) (Kassar-Duchossoy et al., 2004).

MyoD

expression is eventually rescued through a Pax3 dependent mechanism, as
MyoD is not activated in the trunk or limbs of Myf-5/Pax3 double mutants
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(Tajbakhsh et al., 1997).

It should be noted however, that in Pax3 mutant

embryos, myogenic progenitors fail to migrate from the somite to the limb, and
therefore may not receive the proper signals to activate MyoD (Daston et al.,
1996b). A lacZ transgene, driven by the CE and promoter of MyoD called 258/2.5lacZ is active in Myf-5 null embryos and is a target of Pax3 dependent rescue.
Mutation of two, 15bp segments toward the 3' end of the CE results in poor lacZ
expression in the trunk in Myf-5 null embryos (Chen and Goldhamer, 2004a).
Taken together, the CE is responsive to the Pax3 pathway through a 30 bp
internal segment. This internal segment is also a target of Myf-5 activation, due
to a lack of lacZ expression in Pax3 null embryos (Kucharczuk et al., 1999).

As

mentioned above, the CE is sufficient to drive lacZ expression in either the
absence of Myf-5 or Pax3, but the CE is not necessary. The kinetics of Pax3
dependent MyoD expression is the same in wild type embryos or those lacking
the CE or the DRR, demonstrating that neither the CE nor the DRR are exclusive
targets of Pax3 dependent rescue of MyoD expression (Chen et al., 2002; Chen
and Goldhamer, 2004b). Analysis of MyoD expression in the new mouse lines
lacking both MyoD enhancers and Myf-5 will asses whether there are other
elements responsive to the Pax3 pathway.
In order to fully understand the transcriptional control of MyoD, the
regulatory regions must be identified and characterized.

Because of the

conflicting data from lacZ transgenic and knockout experiments in mice regarding
the function of each enhancer, a CE and DRR double enhancer knock out line
has been created, called MyoDΔCEDRR. MyoDΔCEDRR/ΔCEDRR embryos are assayed
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for their MyoD expression profile to uncover any redundant transcriptional control
abilities of the enhancers.
Given that 24kb of DNA upstream of MyoD drives transgene expression
faithfully, and because other enhancers may exist between the CE and DRR, the
15kb of genomic DNA between the two enhancers, including the enhancer
elements themselves, are deleted in a related mouse line named MyoDΔCE15DRR
The

two

homozygous

mutant

lines,

MyoDΔCEDRR/ΔCEDRR

and

MyoDΔCE15DRR/ΔCE15DRR exhibit the same MyoD expression profile as CE single
knockouts, aside from a slight myotomal delay in expression. This shows at least
one unknown enhancer exists, and it does not lie in the 15 kb of genomic DNA
between the two enhancers.

MyoDΔCE15DRR/ΔCE15DRR

and MyoDΔCEDRR/ΔCEDRR

embryos also exhibit the same kinetics of Pax3 dependent rescue of MyoD
expression as wild type embryos.
Knowing that other enhancers are controlling almost all aspects of
embryonic MyoD expression, a computer database search was performed in an
effort to identify evolutionarily conserved sequences and active histone
modifications in the 2Mbp surrounding the MyoD locus. The results implicate the
introns of MyoD as possible enhancers due to conservation across species,
positive epigenetic modifications, and numerous binding sites for relevant
transcriptional activators.
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3.3 Materials and Methods:

MyoD CE targeting vector creation

All plasmid backbones are pBluescript II SK+ (Stratagene). A floxed
(flanked by loxP sites) PGKNeo cassette was excised from the plasmid, ploxPneo-1 (provided by Dr. Marissa Bartolomei) via EcoRI (5’ end) and XhoI (3’ end)
double restriction enzyme digest. The resulting overhangs were filled in by
Klenow (New England Biolabs cat# M0212S). This fragment was inserted and
ligated in reverse orientation between two FRT sites in the loxP2-FRT2/BSIIPSK
plasmid (provided by Dr. Mazakazu Yamamoto), previously blunt end linearized
by EcoRV.
The FRT-loxP-PGKneo-loxP-FRT (FLneoLF) portion of the plasmid was
removed via NotI and EcoRI sequential digests and inserted into p5’enh3’EB
(created by Dr. Jennifer Chen (Chen and Goldhamer, 2004b)). This plasmid
contains 7.3 kb of mouse genomic DNA containing the CE. The 258 bp core
enhancer fragment was excised by BamHI and EcoRI sequential digests. The
FLneoLF fragment was inserted and ligated into the space previously occupied
by the CE, and was flanked by 3.7kb of genomic DNA on the 5’ (upstream) side
and 3.6kb on the 3’ (downstream) side. The resulting ligation product was called
p5’FLneoLF3’.

A thymidine kinase (tk) cassette was added to the 3’ end of

p5’FLneoLF3’ at the XhoI site.
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The plasmid, p5’FLneoLF3’tk, was grown in NM544 electrocompetent
bacteria and the plasmid was isolated using Qiagens EndoFree Maxi Kit, as per
manufacturers’ instructions.

Mouse chimera creation

The targeting vector was linearized by NotI and suspended in TE at a
concentration of 1µg/µl and delivered to the University of Connecticut Health
Center

(UCHC)

Gene

Targeting

and

Transgenic

Facility

(GTTF)

for

electroporation into a custom line of mouse embryonic stem cells. The targeting
of the core enhancer for homologous recombination occured on a chromosome
already lacking the DRR. The GTTF created a hybrid ESC line by crossing mice
lacking the DRR, maintained on a 129SvJ background, with 129SvEv mice.
Blastocysts were collected to create the new ESC line. The CE targeting vector's
homology arms come from the 129SvJ strain, with the intended purpose of
enhanced targeting of the correct chromosome.
ESC clones were screened for proper recombination via BclI digest and
Southern blot on the 5’ side.
mouse

genomic

DNA

The southern probe was PCR amplified from

using

the

TGAACAAAAGGGGATGAGATTCC-3'

forward
and

primer

reverse

primer

5'-GGCGGATCC
5'-CGCGAATT

CAGGAACCACCCTAAAGATCCACC-3'. The resulting fragment was subcloned
in pBS SK+ plasmid.
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The 3' end of the recombination event was assayed by nested long range
PCR.

The external PCR primer sequences are

5'-AGTAGAAGGTGGC

GCGAAGG-3' and 5'-TCAAGCCGGCCACCATAAAG-3'.
primers

are

5'-TCATTCAGGAGAGCCTTTGTT-3'

ATGTGTGCGAG-3'.

and

The internal PCR
5'-TGGATGTGGA

The final amplicon is 4.6 kb in length.

The Invitrogen

Elongase system (cat # 10480-010) was used for long range PCR.

Mouse breeding

Chimeric mice were received from the UCHC GTTF and selected for
breeding based on coat color composition as an indication of targeted cell
contribution to the chimeric mice. Chimeras were mated with FVB (albino) mice
in order to generate offspring with colored coats indicative of germline
transmission. These pups were genotyped via tail snips, DNA isolation and PCR
for both the CENeo and DRRloxP alleles. Successful germline transmission also
demonstrated if the correct chromosome was targeted such that if both alleles
travel together , the correct chromosome was targeted.
CENeo male mice were crossed with HprtCre females (Jax stock #004302)
and R26Flpe females(Jax stock #003946) to generate MyoDΔCE15DRR/+ and
MyoDΔCEDRR/+ mice, respectively. Offspring harboring the recombined CE locus
were interbred for expansion of stock animals and for staged collection. Timed
matings were set up at night, with noon following the morning of a vaginal plug
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considered E0.5. The separate knock out lines were also mated to Myf-5Neo (S.
Tajbakhsh) mice in order to create double heterozygous mice.

Embryo harvesting and staging

Pregnant female mice were sacrificed following IACUC approved
protocols. Mice were anesthetized before cervical dislocation. The uterus was
removed and placed into dishes filled with RNAse free PBS. Individual embryos
were collected and placed into 2% PFA in PBS overnight at 4oC on a shaker.

PCR analysis of genomic DNA from tail snips and embryo yolk sacs

The yolk sacs from each embryo were placed in 1.5ml tubes followed by
Proteinase K digestion. The next day, DNA was purified via diatomaceous earth
extraction.
PCR primers used for genotyping:
MyoDΔCE15DRR forward 5'- CTTGGAACCACACTACCTCAAGG-3' reverse 5'CCAGA TAGATGTCTCCCAGGCTTG-3' to create 350 bp product
MyoDΔCEDRR forward 5'- CTTGGAACCACACTACCTCAAGG-3'
reverse 5'- GTTCCTCTCATGCCTGGTGTTTAGG-3' to create a 230 bp product
Myf-5Neo

forward

5’-CGTTGGCTACCCGTGATATT-3’

CAGCTCAGCTTTGTGTGCTC-3’to create a 670bp product.
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and

reverse

5’-

Myf-5 Wild type forward 5'-TGAAGGATGGACATGACGGAC-3' and reverse 5'TGACCTTCTTCAGGCGTCTACG-3' to create a 300bp product

DIG-labeled RNA probe creation for in situ hybridization

The plasmid, mMyoD-MS/BSIIPSK, contains the 3' portion of the MyoD
cDNA, and was provided by Dr. Masakazu Yamamoto. The cDNA portion of the
plasmid was PCR amplified using standard conditions, and used the M13 forward
and reverse primers. The PCR product was run on an agarose gel. The product
band was cut from the gel and purified, using the Macherey-Nagel NucleoSpin
Gel and PCR clean-up kit, as per manufacturers instructions (ref # 740609.10).
The purified product was PCR amplified as previously stated and repurified.
Digoxigenin labeled mRNA was created using the purified PCR product as
the template, with a labeling kit by Roche (cat # 11 277 073 910) and using T3
and T7 polymerase to generate sense and anti-sense probes.

In situ hybridization for MyoD transcripts

Gentle rocking of embryos occurred during all following incubations.
Embryos were fixed in 2% paraformaldehyde in PBS at 4°C overnight. Embryos
were rinsed and dehydrated in a gradient of methanol mixed with PBT (PBS with
0.1% Tween) (25%, 50%, 75% and 100% methanol) for 10 minutes each.
Embryos were stored at -20°C in 100% methanol until needed. Embryos were
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returned to room temperature and rehydrated in a reverse gradient in methanol
and PBT.

For better probe penetration, embryos were digested in 10µg/ml

ProteinaseK/PBT for 20 minutes, rinsed in PBT, then fixed in 0.2%
glutaraldehyde/4% paraformaldehyde/PBT for 20 minutes. Following rinses in
PBT, embryos were incubated in a 1:1 mix of PBT and prehybridization buffer,
followed by 100% prehybridization buffer for over 1 hour (minimum 2 hours
yielded best results) at 70°C. The prehybridization buffer is composed of 50%
formimide, 5xSSC, 2%SDS, 2% Roche Blocking Reagent (cat#11096176001),
250µg/ml yeast tRNA, 100µg/ml heparin, in RNase free H2O.

Digoxygenin

labeled RNA probe was then added to a concentration of .25µg/ml and incubated
at 70°C overnight.
Embryos were washed in SolutionX ( 50% formamide, 2XSSC, 1% SDS) 5
times, 20 minutes per wash, at 70°C.

Embryos were then incubated for 20

minutes as 70°C in a 1:1 mix of SolutionX and MABT (for 50ml of MABT mix .29g
maleic acid, .218g NaCl, .5ml 10% Tween20, and H20 to make 50 ml and
adjusted pH to 7.5 with NaOH). Embryos were then washed 4 times at 5 minutes
per wash in MABT at room temperature.
Embryos

are

incubated

in

2%

Roche

Blocking

Reagent

(cat

#11096176001) in MABT for 30 minutes at room temperature. Continue with a
two hour room temperature block in 2% Roche Blocking Reagent/20% Fetal
Bovine Serum in MABT. Anti-Digoxygenin-AP Fab were then added to a 1:2000
dilution and incubated at least 1 overnight (2 overnights gives best result) at 4°C.
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Following incubation with the anti-DIG antibody, embryos were washed
four times, at 1 hour per wash in MABT, followed by an overnight wash in MABT,
all at room temperature.
Wash embryos in NTMT (100mM NaCl, 100mM TrisCl pH 9.5, 20mM
MgCl2, 0.2% Tween 20) three times, ten minutes per wash at room temperature.
Replace NTMT with BM Purple (cat #11442074001) and develop color to
appropriate level, usually 6-8 hours. After color development level is reached,
rinse embryos in NTMT several times to minimize precipitate formation, then
continue rinsing in PBT.

Embryo imaging

Whole mount images were taken using a Lecia MZ FLIII. Images were
captured using a Spot 25.2 2 Mp Color Mosaic camera using Spot Software V4.6
by Diagnostic Instruments. Images were modified using Photoshop CS2.

92

3.4 Results:
3.4.1 Targeting the Core Enhancer for deletion:

To define the compensatory abilities of the CE and DRR or to provide data
that uncharacterized enhancers exist, the CE was targeted for deletion in
mouse embryonic stem cells (ESCs) already lacking the DRR.

ESCs were

created by the UCHC through mating male DRRloxP male mice, maintained on a
129SvJ genetic background, to the cell culture friendly strain, 129SvEv.
Blastocysts created form the mating were collected to create the new ESC line.
The targeting vector, p5’FLNeoLF3’tk, was created to precisely replace the
258bp CE with a Neomycin resistance gene, flanked by loxP sites, all of which
was flanked by FRT sites (Fig 3-1A).

The presence of two different

recombinase targets allows for creation of two different lines from the same
targeting event, described below. The homology arms of the targeting vector
originated from the 129SvJ strain to increase efficiency of targeting the correct
chromosome by sequence similarity. Homologous recombination was assayed
by southern blot on the 5' side and long range nested PCR on the 3' side (Fig.
3-1B and C).
Following germline transmission of the targeted locus, male offspring
were mated with both R26Flp and HprtCre females to produce two different lines
via recombination.

Flippase dependent recombination (Schaft et al., 2001)

removes the floxed Neo cassette, leaving a transcriptionally inert FRT site,
creating the new line lacking both the CE and DRR, MyoDΔCEDRR/+ .
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Cre

recombination (Nagy, 2000) of the MyoDCENeo allele when located on a DRRloxP
chromosome, results in removal of the 15kb of DNA from the 5’ end of the Neo
cassette to the 3’ end of the former site of the DRR, called MyoDΔCE15DRR/+ (Fig
3-2A and B).

The new lines were expanded by mating with FVB mice.

Heterozygous and homozygous mutant mice were all equally viable.

3.4.2 MyoD mRNA expression in MyoDΔCEDRR/ΔCEDRR embryos

In order to observe the effect on MyoD expression patterns when both
known enhancer elements were removed, MyoDΔCEDRR/+ mice were intercrossed,
and embryos from pregnant females were collected between E9.5 and E12.5.
Noon following the morning of vaginal plug detection was considered E0.5 for
staging purposes. Whole mount in situ hybridization was performed to visualize
MyoD transcripts. Successful validation of the probe and the sense control probe,
a sequence that is identical to MyoD mRNA and should not produce a specific
signal is shown in Fig 3-3.
Comparisons between wild type and heterozygous embryos show no
phenotypic difference, meaning haploinsufficiency is not an issue and allows for
heterozygous embryos to be used as a reference point in some figures (Fig 3-4).
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Figure 3-1. Targeting the Core Enhancer for deletion

The 258bp Core Enhancer lies approximately 22 kb upsteam of the MyoD locus
and was targeted for precise removal by the targeting vector, p5’FLneoLF3’tk.
The targeting vector contains a 3.7kb 5’ homology arm, ending at the EcoRI site
5’ of the CE, and a 3.6kb 3’ homology arm, that ends at the XhoI site 3’ of the CE.
After homologous recombination, the CE is replaced by a PGKNeo cassette
flanked by loxP and FRT sites, in reverse orientation in respect to the
transcriptional orientation of MyoD. Desired recombination on the 3’ side was
assessed via long range nested PCR, where 3 of the four lanes show the
targeted 10kb band size along with the wild type 8.5kb band (Fig 3-1B).
Detection of proper recombination was carried out on the 5’ end by BclI digest
and southern blot using the DNA probe depicted. Fig. 3-1C shows correctly
targeted clones in lanes 2, 4 and 5.
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Figure 3-2A
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Figure 3-2. Creation of MyoDΔCEDRR and MyoDΔCE15DRR mice

Following germline transmission of the CENeo allele, two different recombination
events need to take place to create the two new mutant lines. CENeo male mice
were mated with R26Flpe female mice to recombine out the PGKNeo cassette,
creating the MyoDΔCEDRR/+ line (Fig 3-2A).

Appropriate recombination was

assessed via PCR using primers F1 and R1, that generate a 210 bp band if
recombination took place, while non recombinant alleles would generate an
approximate 430bp fragment.
CENeo male mice crossed with HprtCre females to produce the MyoDΔCE15DRR/+
line. Proper recombination was assessed via PCR using primers F2 and R2, to
create a 350bp product if recombination took place, and no product if
recombination did not take place as the primers lie approximately 15kb away
from each other in the genome.
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Figure 3-3
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Figure 3-3. Validation of MyoD in situ probe

E12.5 littermate embryos hybridized with either the sense or anti-sense RNA
probe to detect endogenous MyoD mRNA. The antisense probe complimentary
base-pairs with MyoD transcripts and produces the expected signal profile. The
sense probe RNA sequence is identical to MyoD transcripts and serves as a
control against non specific binding of the anti-sense probe or hybridization to
genomic DNA. Note the lack of and real signal, with only minor background, in
the sense probe panel.
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Figure 3-4
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Figure 3-4. MyoDΔCE15DRR heterozygote and Wild Type MyoD mRNA profiles

In situ hybridization for MyoD transcripts of heterozygous MyoDΔCE15DRR/+
embryos was compared to wild type embryos to asses any haploinsufficiency.
E10.5 (A and B) and E12.5 (C and D) embryos showed no significant differences
in timing or intensity of expression between heterozygous and wild type embryos.
In panels A and B, the yellow arrows indicate the forelimb buds and the green
arrows indicate the hindlimb buds. In panels C and D, the red arrows indicate
the branchial arches.
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A comparison of MyoDΔCEDRR/ΔCEDRR and wild type embryos between E9.5
and E12.5 shows that the CE and DRR are not the only enhancers of MyoD and
they do not compensate for each other when one is absent. Generally, the
phenotype in MyoDΔCEDRR/ΔCEDRR

embryos is a combination of CEloxP and

DRRloxP single knock out phenotypes, described previously (Chen et al., 2002)
(Chen and Goldhamer, 2004b). At the onset of MyoD expression in the myotome
and branchial arches at E9.5, MyoD expression is absent in both areas in the
mutant embryos (compare Fig 3-5A to 3-5E).
expression

is

the

only

significant

The lack of early myotomal

phenotypic

difference

between

MyoDΔCEDRR/ΔCEDRR mutant embryos and either CEloxP or DRRloxP single mutants.
In either single knock out, the timing of myotomal MyoD expression is identical to
wild type embryos (Chen et al., 2002; Chen and Goldhamer, 2004b). It can now
be said that timely activation of myotomal MyoD expression is dependent on
either the CE or DRR being present. By E10.5, the epaxial signal has largely
recovered, with only a mild reduction in signal intensity in the mutant embryos
similar to DRRloxP embryos. The hypaxial lineage that gives rise to muscle beds
in the limb buds and branchial arches still exhibits a pronounced delay, with no
signal in limb buds of MyoDΔCEDRR/ΔCEDRR embryos at E10.5(Fig 3-5 B and F). At
E11.5, MyoD expression is largely identical between wild type and mutant
embryos, with a slight delay in hindlimb expression in the mutants (Fig 3-5 C, G).
The expression profile of MyoD eventually recovers in mutant embryos by E12.5
(Fig 3-5 D and H) and is nearly indistinguishable to wild type embryos.
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Figure 3-5
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Figure 3-5. Timeline of MyoD expression in MyoDΔCEDRR/ΔCEDRR

and wild

type embryos

Whole-mount in situ hybridization for MyoD mRNA in WT embryos (A-D) and
litter mate MyoDΔCEDRR/ΔCEDRR embryos (E-H). At E9.5, (A and E) branchial arch
expression is present in the wild type embryo and absent in the mutant, as seen
in the magnified areas (red boxes).

Red arrows indicate early myotome

expression in the wild type embryo (A) that is absent in the mutant embryo (E).
At E10.5, branchial arch expression (yellow arrow) still lags in mutants. Forelimb
signal (green arrows) is present in wild type (B) embryos and lacking in mutant
embryos (F). E11.5 forelimb expression is similar between (C) and (G), while
hindlimb expression, red arrows, still lags in the mutant. By E12.5, (D and H)
embryos have nearly identical expression patterns, although the expression level
is slightly reduced in the mutant.
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3.4.3 Pax-3 dependent rescue of MyoD expression is independent of the CE
and DRR

In the absence of Myf-5, MyoD expression is delayed in the myotome by
approximately 2 days, with no effect on the hypaxial lineages (Tajbakhsh et al.,
1997).

The factor that rescues MyoD expression in Myf-5 mutants is Pax3. In

the absence of Pax3, limb myogenesis fails, as myogenic progenitors can’t
migrate from the somite to the limb due lack of activation of downstream target
genes, such as c-met (Bober et al., 1994b) (Daston et al., 1996a). Embryos
lacking both Myf-5 and Pax3 fail to activate MyoD in the body, due to the
dependence of either gene to activate transcription of MyoD. MyoDΔCEDRR/+;Myf5Neo/+ mice were intercrossed to create MyoDΔCEDRR/ΔCEDRR;Myf-5Neo/Neo embryos
in order to determine if the CE and DRR are the only elements responsive to
Pax3 dependent activation. E11.25 embryos lacking only Myf-5 exhibit the early
stages of Pax3 dependent myotomal MyoD expression (Figure 3-6 A,B).

In

MyoDΔCEDRR/ΔCEDRR;Myf-5Neo/Neo embryos at this stage, myotomal expression is
nearly identical to Myf-5Neo/Neo embryos. The delay observed in limb expression is
due only to the absence of the CE and DRR. By E12.5 (Figure 3-6 C-E), Pax3
dependent MyoD rescue is complete, even with the absence of known MyoD
enhancers.
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3.4.4 The 15kb of DNA between the CE and DRR is not involved in
embryonic transcription of MyoD or in Pax3 dependent expression

The results from the discrete enhancer knock outs show that at least one
other enhancer exists. This was a possible result, so the targeting vector was
designed to allow for precise removal of the CE and DRR, but also for removal of
the genomic sequence between the CE and DRR.
In the new line, called MyoDΔCE15DRR, both the CE and DRR are absent,
along with the intervening DNA. The expression profile of homozygous embryos
is identical to the that of embryos lacking only the CE and DRR (compare Figures
3-5 to 3-7). The delay and eventual recovery of MyoD expression in the hypaxial
lineage mirrors that of MyoDΔCEDRR/ΔCEDRR embryos.
We also investigated whether Pax3 dependent rescue of MyoD
expression occurs though the sequence between the CE and DRR. Figure 3-8
shows the same delay and rescue kinetics of MyoD expression exists in
MyoDΔCE15DRR/ΔCE15DRR;Myf-5Neo/Neo as in Myf-5Neo/Neo embryos.
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Figure 3-6
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Figure 3-6. Removal of the CE and DRR does not affect Pax3 dependent
rescue of MyoD expression

At E11.25 (A-C) early rescue of myotomal MyoD expression is underway in
Myf-5Neo/Neo and MyoDΔCEDRR/ΔCEDRR;Myf5Neo/Neo embryos (red arrows). Delay of
MyoD expression in limb buds and branchial arches is due to the lack of the CE
and DRR, and does not reflect the absence of Myf-5.

By E12.5 (D-F), the

myotomal expression of MyoD is similar between MyoDΔCEDRR/ΔCEDRR;Myf5Neo/Neo
and Myf5Neo/Neo embryos. The aberration in expression in the trunk is due to the
rib defect seen in Myf-5Neo/Neo only embryos (compare D and E, red arrows).
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Figure 3-7
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Figure 3-7. Whole mount in situ hybridization for MyoD mRNA in
MyoDΔCE15DRR/ΔCE15DRR and wild type embryos

Wild type embryos (A-D) are compared to MyoDΔCE15DRR/ΔCE15DRR embryos (E-H).
Red panels in A and D indicate zoomed in areas showing either a presence or
absence of MyoD signal in the branchial arches. In B and E, branchial arch
staining (yellow arrows) is present in the mutant embryo, but is not as advanced
as the wild type embryo. Green arrows show the delayed activation of MyoD in
the forelimb buds. By E11.5, (C and G), mutant embryos largely mimic the wild
type expression pattern. There is less expression in the hindlimbs (red arrow) in
mutants than in wild type embryos. At E12.5 (D and H), expression is similar in
both embryos.
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Figure 3-8
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Figure 3-8. Pax3 dependent MyoD expression occurs normally in
MyoDΔCE15DRR/ΔCE15DRR embryos

At E11.25 (A-C) early myotomal MyoD expression in MyoDΔCE15DRR/ΔCE15DRR
embryos is identical to embryos with or without the CE and DRR. Limb bud
expression differences (B and C versus A) result from the absence of the CE,
DRR and intervening sequence.

Myotomal expression, dependent on Pax3

(compare B and C) are identical (red arrows).

At E12.5, myotomal MyoD

expression is nearly identical between MyoDΔCE15DRR/ΔCE15DRR and wild type
embryos(D-F). The only difference in myotomal expression is due to the Myf5Neo/Neo genotype (red arrows) that causes rib defects involving intercostal
muscles.
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3.4.5 Genome Database Analysis

The

lack

of

dramatic

phenotypes

in

MyoDΔCEDRR/ΔCEDRR

and

MyoDΔCE15DRR/ΔCE15DRR embryos led us to search for enhancer regions using
database analysis.

Two million bases, centered on the MyoD locus, were

analyzed for conservation of DNA sequence among mammals (rat, dog, human,
orangutan, and horse), a marsupial (opossum), the chicken, and the stickleback
fish. Active chromatin markers from C2C12 myoblasts were also considered in
the search for enhancer elements.
The Genome Browser, created at The University of California, Santa Cruz,
allows for integration of genome data from various groups.

We looked for

sequence conservation across a number of species, as this is a strong indicator
of important sequences.

The CE and DRR were known to be conserved

between humans and mice, and they are highly conserved among most
mammals analyzed (Figure 3-10 A and B). Included in the analysis was the level
of mono-, di-, and tri-methylation of the protein tail of histone 3, lysine 4 (H3K4) in
the C2C12 cell line.

This specific epigenetic marking is indicative of active

chromatin, and forced methylation of H3K4 leads to gene activation (Snowden et
al., 2002; Towbin et al., 2012). H3K4 methylation is also a strong epigenetic
indicator of enhancers (Bernstein et al., 2006). Specifically, H3K4 di and trimethylation have been proven to mark active enhancers (Pekowska et al., 2011).
Using a myoblast cell line gives more relevant data about portions of the genome
available for transcription factor binding, and thus transcriptional control.
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In the 2 million bases flanking MyoD, we found no evolutionarily
conserved sequences that were also highly methylated outside of protein coding
genes.

Some of the conserved genes have active histone modifications, while

many did not. The heavily methylated, conserved genes, such as Emp3, and
Gys1, are both expressed in muscle cells. Emp3 is involved in cell proliferation
and Gys1 encodes a metabolic gene, glycogen synthase (Villarroel-Espíndola et
al., 2013).

The locally non-methylated, conserved genes encode proteins

involved in various non-myogenic organ systems, such as Otog, a gene involved
in inner ear development (Schraders et al., 2012).
Sequence conservation in non-protein coding regions of the genome
indicates important regions that can contain regulatory elements. The four MRFs
likely arose from gene duplication and divergence during evolutionary history
(Dermitzakis and Clark, 2001). Myf-5 has high sequence and functional similarity
to MyoD, and Myf-5 has important enhancers in its introns (Carvajal et al., 2001).
The idea that intronic enhancers may exist for MyoD is supported by unpublished
observations by Masakazu Yamamoto. In a targeted mutation creating a new
MyoD allele, the exons and two introns of MyoD are flanked by loxP sites,
followed by the GFP gene.

Following Cre recombination, the MyoD gene is

removed, and GFP should be driven by the local enhancers. However, GFP
expression does not occur in myogenic regions of the embryo, perhaps due to
the removal of intronic enhancers. The MyoDiCre allele, used in the previous
chapter, shows robust activity in myogenic cells.

However, this allele only

removes exon 1 and the first 42 nucleotides of intron 1 (Kanisicak et al., 2009).
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Interestingly, sequence analysis of MyoD shows the highest levels of H3K4 trimethylation occurring in intron 1. There are also several short regions in intron 1
that are evolutionarily conserved across several mammalian species (Fig 3-9).
Intronic sequences were compared for any similarity between MyoD and
Myf-5, and no significant similarities were found (data not shown). However,
transcription factor binding sites, based on sequence only, are plentiful in intron 1
of

MyoD,

and

many

of

these

motifs

are

present

in

intron

2

(http://jaspar.genereg.net/). Binding sites of interest include Klf4, Sp1, En1, Ap1,
Pax2, Sox 5, 10, and 17. Klf4 is an indicator of stem cell like capacity in hESC
cultures and is used in formation of induced pluripotent stem (iPS) cells
(Tahmasebi et al.). Sp1 is known to regulate expression of many genes involved
in cell proliferation, apoptosis, and differentiation (Chu, 2012). En1, or engrailed,
is a homeobox containing transcription factor involved in dorso-ventral patterning
of the limb field during embryogenesis (Hanks et al., 1998). Ap1 controls cell
division and cell death decisions (Alani et al., 1991) and is known to work with
Pax2, another vital factor in embryogenesis (Zhang et al., 2012). Sox 5 plays a
role in differentiation during embryogenesis and Sox 17 works to inhibit Wnt3a
singaling (Vervoort et al., 2012). The computational data indicates that putative
binding elements for relevant factors exist within the introns of MyoD and warrant
further study.
The lack of positive epigenetic modifications, and presence of negative
epigenetic changes were also examined in non-myogenic cell types.

H3K4

methylation is absent in neural, heart, and liver tissue, as well as erythroblasts

116

and megakaryocytes. In fact, all non-myogenic cell types exhibited high levels
of transcriptionally repressive marks, such as H3K27 and H3K9 tri-methylation
(Barski et al., 2007). A marker of active chromatin is acetylation of lysine in H3.
C2C12 cells contain H3K9ac, while all other cells types analyzed, including, brain,
liver, and heart tissue, lacked this positive epigenetic mark.
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Figure 3-9

118

Figure 3-9. Database analysis of the MyoD locus reveals sequence
conservation across species and positive epigenetic markings

Data obtained from the University of California, Santa Cruz, Genome Browser.
Analysis of the genomic sequence surrounding the MyoD locus includes
sequence conservation across species along with active histone modifications in
the C2C12 immortal myoblast cell line.
site,

Abbreviations: (STS) sequence tagged

(EST) expressed sequence tag, (H3K4me3) histone 3, lysine 4, tri-

methylation. The MyoD coding region shows high sequence similarity across
species in exons, with high levels of H3K4me3 in introns 1 and 2. Intron 1 also
shows sequence conservation across several species.
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Figure3-10
A

B
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Figure 3-10. Database analysis of the CE and DRR reveals high sequence
similarity across species

Sequence images of the murine CE (A) and DRR (B). The discrete enhancer
areas are boxed in red. Sequence conservation is high across species and is
higher than outside of the boxed regions.
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3.5 Discussion:

When the 24 kb of human sequence upstream of MyoD is attached to
either GFP or lacZ and placed in the mouse genome, reporter gene expression
almost flawlessly mimics endogenous MyoD expression (Chen et al., 2001).
Other transgenic experiments demonstrated distinct functions between the two
known MyoD enhancers contained in the 24kb of sequence. The CE transgene
showed activity concurrent with initiation of MyoD expression, and the DRR was
active in differentiating muscle (Chen et al., 2001). When either of the discrete
enhancers were eliminated from the mouse genome, only slight defects occurred,
leading to the hypothesis that the enhancers could compensate for each other
when one was absent (Chen et al., 2002; Chen and Goldhamer, 2004b). In this
present study, we have shown that at least one other uncharacterized enhancer
exists, and that they are largely responsible for the proper spatio-temporal
transcription profile of MyoD during embryogenesis.

This study is a striking

example of necessity versus sufficiency. The known enhancers are sufficient to
drive reporter gene expression in a pattern that mimics MyoD, but none of the
known enhancers are necessary for it.
Recent studies regarding upstream regulators of MyoD show pronounced
muscular defects after eliminating trans acting regulators that have been shown
to bind the CE or DRR. Positive regulators, such as YB1/p32 (Song and Lee,
2010), Six1/4 and Eya1/2 (Grifone et al., 2005), BMAL1/Clock (Andrews et al.,
2010) (Zhang et al., 2011), Pitx2 (L'Honore et al., 2010), and the transcriptional
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repressor Sim2 (Metz et al. 2006, Havis et al. 2012) have demonstrable effects
on MyoD transcription. Although binding of these various factors to the CE have
been shown in vitro, the CE may not be the only target, and the introns or other
DNA elements may be binding sites for these factors. It should be noted that
some of the previous studies examined postnatal transcriptional control, and that
aspect of myogenesis has not been addressed in this study. The CE's function
may be to control the circadian oscillation of MyoD expression in adult muscle,
via binding of CLOCK1/BAML to the CE, however, only the CE and 6kbs of DNA
upstream of MyoD were assayed for binding (Andrews et al., 2010). In mice
lacking only the CE, CEloxP/loxP, MyoD expression oscillation is only dampened,
not eliminated (Zhang et al., 2011). In all studies mentioned above, it may be
that DNA elements outside of the CE and DRR are involved as well.
In this study, it has been shown that in the absence of both the CE and
DRR, MyoD expression is largely unperturbed, with only a delay in MyoD
expression in the limb buds and branchial arches. This phenotype was also
observed when only the CE is removed (Chen and Goldhamer, 2004b).
MyoDΔCE15DRR/ΔCE15DRR embryos displayed MyoD expression identical to the
pattern in MyoDΔCEDRR/ΔCEDRR embryos. This result is not unexpected, as there
have been no studies implicating the sequence between the CE and DRR as a
potent regulator of MyoD expression.

Now there is definitive proof that no

necessary regulation of MyoD occurs via this DNA sequence. There is a portion
of F3 that remains in MyoDΔCE15DRR/ΔCE15DRR animals that may have regulatory
abilities.

The CE was found to be the most potent portion of F3, but the
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approximately 1.5 kb of F3 that remains could partly control transcription
(Goldhamer et al., 1995).
The targets of the Pax3 dependent rescue pathway of MyoD expression in
the absence of Myf-5 was investigated in our two now mouse lines. We have
shown that the rescue kinetics are similar between wild type embryos and both
MyoDΔCEDRR/ΔCEDRR and MyoDΔCE15DRR/ΔCE15DRR embryos.

These results are

striking when compared to numerous transgenic analyses.

In a fine scale

transgenic mapping study of the CE, where only the CE and proximal promoter of
MyoD controll lacZ expression, 15 bases of the CE were replaced with a linker
sequence at a time. Two adjacent sequences, when mutated, both resulted in
the loss of reporter expression in the myotome and myotome derived muscles.
(Kucharczuk et al., 1999) This mutated construct showed no activity in the trunk
of Myf-5 null embryos, showing the exact portion of the CE that is a target of
Pax3 rescue (Chen and Goldhamer, 2004a), albeit not the only target.
There remains the possibility of regulatory element in the 2kb upstream of
the CE. Transgenic studies using 24kb of human DNA upstream of MyoD, with a
4kb fragment removed, to drive lacZ expression exhibited reporter gene
expression delay throughout the embryo (Chen et al., 2001). Importantly, near
the center of this 4kb deleted fragment lies the CE. Both the MyoDΔCEDRR/ΔCEDRR
and MyoDΔCE15DRR/ΔCED15RR lines retain the 2 kb portion.

Database analysis

shows the 2 kbs directly upstream of the CE contain a similar amount of H3K4 trimethylation as the CE itself, but the amount of sequence conservation between
species is higher in the 258 bps of the CE (Figure 3-10A).
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Database analysis supports the hypothesis that enhancers exist in the
introns of MyoD, particularly in intron 1. Sequence analysis of the MyoD shows
that of all the surrounding sequence analyzed, the highest levels of H3K4 trimethylation, an epigenetic marker of enhancers, occurs in the introns. There is
also a short region in intron 1 that is evolutionarily conserved across several
mammalian species and contains multiple, unproven, transcription factor binding
sites. These active chromatin modifications are not present in non-muscle cell
types.

In non-muscle cell types, the entire MyoD locus contains repressive

chromatin modifications, such as H3K9 and K3K27 tri-methylation. A follow up
experiment is warranted to address intronic enhancers. Either a transgenic study
where the introns drive reporter gene expression, or targeting the MyoD locus to
replace the entirety of MyoD with a reporter gene can be performed.
The intricate pattern and timing of MyoD expression throughout the entire
embryo implies a more complex regulatory system than currently known. The
regulatory network of the conserved family members, Myf-5 and Mrf4, has
proven to be quite complex, and this study indicates that MyoD may have
similarly complex regulation. Myf-5 enhancer elements span over 140kb and
there are distinct roles for each of the 19 enhancers identified in location of
expression, timing of expression, or both (Buchberger et al., 2003; Carvajal et al.,
2001; Hadchouel et al., 2003; Summerbell et al., 2000). Also known is that some
enhancers of Myf-5 are contained in the introns (Carvajal et al., 2008). The
signaling environments that lead to MyoD expression are different at the three
main areas of embryonic myogenesis, namely,
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the head, trunk and limbs

(Moncaut et al., 2013).

This variability in regulatory factor environments implies

multiple enhancers and is consistent with the findings presented here, as we
demonstrated that the embryonic transcriptional regulation of MyoD is more
complex than previously shown.
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Chapter 4 MyoD lineage ablation and the role of myogenesis in proper rib
development

4.1 Abstract:

In order to address the mode of redundancy between MyoD and Myf-5, we used
the MyoDiCre allele to activate the Cre dependent diphtheria toxin (R26DTA) gene
resulting in the death of any cell that activates the MyoD locus Preliminary data
at E18.5 shows the complete absence of skeletal muscle, evidenced by a lack of
Myosin Heavy Chain expressing cells. This result is in contrast to previously
reported Myf-5Cre;R26DTA embryos, where myogenesis occurs and embryos are
born with functional muscle, indicating that all myogenic cells express MyoD, but
not Myf-5, during development.

Interestingly, there was an unexpected rib

malformation phenotype in MyoDiCre;R26DTA embryos. This observation led to
analysis of the dependency of rib development on appropriate muscle formation
in the myotome. We examined the rib malformation phenotype in Myf5loxP/loxP;MyoDiCre/Neo, Myf-5Neo/Neo;MyoDiCre/Neo and MyoDiCre/+;R26DTA embryos,
three genotypes known to affect myotome formation and development at different
times. It appears that normal rib development requires the timely formation of
the myotome, as well as continued presence of intercostal muscles, such that the
earlier the perturbation in myotome formation and development, the more severe
the rib defect.
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4.2 Introduction:

Lineage Ablation

Since the seminal research regarding the genetic control of embryonic
myogenesis, there has been an open question regarding the mode of
redundancy between MyoD and Myf-5. These transcription factors are largely
similar in DNA sequence, and share an identical DNA binding domain. When
either MyoD or Myf-5 is deleted from the mouse genome, myogenesis occurs
almost normally, and embryos are born with functional skeletal muscle (Braun et
al., 1992; Rudnicki et al., 1992a). However, when both genes are deleted, no
skeletal muscle forms in the embryo. (Rudnicki et al., 1993).

The question

became, are MyoD and Myf-5 functionally redundant in the same cells, or are
there redundant lineages, ie a MyoD dependent and a Myf-5 dependent lineage?
Recently, the two separate lineage hypothesis was supported by the
diphtheria toxin (DTA) induced cell death after activation of the Myf-5 locus
(Gensch et al., 2008; Haldar et al., 2008). The Cre gene was knocked into the
Myf-5 locus, where activation results in cre-mediated recombination of R26DTA,
and diphtheria toxin production, causing cell death by inhibiting protein
translation via elongation factor 2 (Ivanova et al., 2005; Pappenheimer, 1977).
Skeletal myogenesis still occurs in these embryos, via a Myf-5 independent
lineage.
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Putting lineage ablation under the control of the MyoD locus was
performed using MyoDiCre/+;R26DTA embryos and results in the lack of skeletal
muscle at E18.5. This preliminary data shows that all cells of the myogenic
lineage activate the MyoD locus.

Rib Development

The original Myf-5 knockout allele, Myf-5Neo, resulted in severe, perinatal
lethal, rib defects (Braun et al., 1992). However, MyoDNeo/Neo embryos did not
exhibit a rib phenotype (Rudnicki et al., 1992b).

Thought only to control

myogenesis, the connection between the allele, and the unexpected rib
phenotype was a major point of interest. The Myf-5Neo allele retains the PGKNeo
selection cassette, and it was hypothesized that the disrupted allele affected
expression of other unspecified genes involved in rib development. After a more
discrete allele was created, Myf-5loxP, it was found that the rib defect was
eliminated. The Neo cassette was transcriptionally silencing the physically close
myogenic gene, Mrf4 (Kassar-Duchossoy et al., 2004). Myf-5 and Mrf4 control
the formation of the myotome, and MyoD plays a later role in myotomal
development.
Generally, functional muscle aids in proper embryonic bone growth by
providing static load and contractions to stimulate osteogenesis (Hamrick, 2010).
Aside from the rib truncation phenotype, MyoD-/-;Myf-5Neo/Neo embryos have fused
vertebra, malformed mandibles and palate (Rot-Nikcevic et al., 2006), and close
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proximity of the radius and ulna (presented in Chapter 2). The rib phenotype
appears to be caused by much earlier stages in myogenesis, prior to functionally
contractile muscle formation.

The close proximity of the developing axial

skeleton, arising from the sclerotome, and the myotome, may point to a signaling
pathway between the two, such that the lack of a myotome perturbs signaling
and results in a malformed rib cage. It has been found that the myotome allows
for PDGFA and FGF expression in the sclerotome, and that this activation is
needed to promote rib development (Tallquist et al., 2000; Vinagre et al., 2010).
In embryos with compromised muscle differentiation, rib development is still
affected. When embryos lack Mrf4 and have hypomorphic alleles of Myogenin,
fusion of ribs to the sternum fails, and the ribs are shaped improperly (Vivian et
al., 2000). These two genes are not expressed in axial bones nor the early
myotome, meaning the resulting rib phenotype is dependent only on the failure of
myogenic differentiation.
Here we report that a link between myotome formation and maintenance
impacts the extent of rib development, further strengthening the link between
skeletal muscle and bone development.

134

4.3 Materials and Methods:

Mouse breeding and genotyping

All mouse handling, breeding, and sacrificing were done in accordance
with our IACUC animal care protocol. All separate lines were maintained by
breeding to FVB mice. Cre dependent DTA expressing mice, R26DTA, were
obtained from Jaxson Labs (ID #006631) and expanded through intercrossing.
Offspring were crossed to MyoDiCre/+ animals. Timed matings were set up by
taking the morning of vaginal plug as embryonic day 0.5 or E0.5. The MyoDiCre
allele was detected by PCR using a forward primer (5′-GCGGATCCGAATTC
GAAGTTCC-3′) that lies at the 3′ end of the icre/+2pA cassette and a reverse
primer in intron 1 of MyoD (5′-TGGGTCTCCAAAGCGACTCC-3′), generating a
product of 149 bp. No genotyping was required for the DTA allele, as mice
received were homozygous and the presence of the allele in embryos is evident
based on EGFP expression in the non-recombined allele. The MyoDNeo allele
was detected with the forward primer 5’- TGGATGTGGAATGTGTGCGAG-3’ and
the reverse primer 5’- TCACTGTAGTAGGCGGTGTCGTAG-3’ to create a 420
bp product. The Myf-5Neo allele was detected using the primers 5’-CGTTGG
CTACCCGTGATATT-3’ and 5’- CAGCTCAGCTTTGTGTGCTC-3’ creating a
410 bp product. Myf-5loxP was detected using the primers 5'- GGTGTCT
CCTCTCTGCTGAATCCAGGTAT-3' and 5'-AGGTGCACGCACGTGCTCA
CTGTCTGA-3' to create a 349 bp band.
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Cryostat sectioning

Embryos were isolated and fixed with 4% paraformaldehyde for 3.5 hours
at 4oC. The embryos were rinsed with 4oC PBS 4 times for 20 minutes each. The
fixed muscle was processed through a sucrose gradient of 15% sucrose in PBS
overnight, followed by 30% sucrose in PBS overnight all at 4oC . The processed
tissue was placed into OCT compound and quickly frozen in dry ice cooled
isopentane. The frozen tissue was cryosectioned at 10 μm and either stored at 80oC, or immediately processed for observation.

Immunofluorescence

Skeletal muscle was detected using a mouse anti-Myosin antibody at a
1:250 dilution (Millipore # MAB1628) and a secondary goat anti-mouse red
fluorescent antibody 1:500 dilution (Invitrogen # A-21422). Vector labs MOM kit
(# BMK-2202) was used as per manufacturers instructions after antigen retrieval.
The retrieval process entails a 6 min. soak in -20oC methanol, followed by a 30
minute incubation in 95oC 10mM sodium citrate pH 6. A standard block (1%
BSA, 10% goat serum, 0.1% Tween in PBS) was performed for 2 hours at room
temperature, followed by a 2 hour primary antibody incubation, also at room
temperature.
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4.4 Results:

Embryonic day 18.5 MyoDiCre/+;R26DTA embryos were collected as an end
point assay to determine the size of the MyoD expressing lineage. At this stage,
there was no muscle visible. The gross appearance of the embryos (Fig 4-2)
was similar to the amyogenic embryos in Chapter 2. Sectioning of the embryos
followed by antibody detection of myosin heavy chain, a muscle specific marker,
revealed a complete lack of skeletal muscle in the embryo (Fig 4-1)
The rib defect phenotype seen in MyoDiCre/+;R26DTA embryos was not as
severe as in Myf-5Neo/Neo;MyoDiCre/Neo embryos. Myf-5Neo/Neo;MyoDiCre/Neo
embryos also have a transcriptionally repressed Mrf4 gene, and in the absence
of primary myogenesis, no muscle forms and only rib rudiments or 'nubs' are
formed (Figure 4-2 A red arrow). In MyoDiCre/+;R26DTA embryos, early myotome
development occurs normally. Early myotome formation is under the control of
Myf-5 and Mrf4 as they are turned on at E9, while MyoD is not turned on robustly
until E10. Cell death does not occur instantly, as Cre must be produced, the
R26DTA locus must be recombined and produce the toxin to kill the cell, which
takes at least 24 hours (Saito et al., 2001). This window of myogenesis allowed
for rib outgrowth, however myogenesis ends and the ribs are still severely
truncated (Figure 4-2 B red arrow). In Myf-5loxP/loxP;MyoDiCre/Neo embryos,
primary myogenesis is completely dependent on Mrf4. In these embryos, rib
outgrowth is the most advanced. These embryos still die at birth and have very
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little organized muscle. However, the continual presence of muscle allows for rib
outgrowth (Figure 4-2 C).
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Figure 4-1. Lack of Muscle in limb of E18.5 MyoDiCre/+;R26DTA embryos

10 μm cryostat sections of wild type (D-F) and MyoDiCre/+;R26DTA limbs at E18.5.
Myosin Heavy Chain antibody detection (B and E) show the absence of any
myogenic cells in MyoDiCre/+;R26DTA embryos. Dapi is used to visualize nuclei (A
and D) while (C and F) show phase images. The forearm bones are seen as an
absence of staining in B and in the phase images (C and F). Scale bar
represents 30 μm.
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Figure 4-2

A

B

No 1o MRF

C

MyoDiCre;R26DTA

141

Mrf4 dependent

Figure 4-2. Rib Abnormality Phenotype in E18.5 Embryos with different
MRF mutations

Comparison of rib development in embryos with various myogenic mutations.
There is no MyoD, Myf-5, or Mrf4 expression in (A) and rib development does not
produce more than nubs (red arrow in A). Rib development progresses more in
B (red arrows) when early myotome formation is dependent on Myf-5 and Mrf4
until

the

onset

of

MyoD

expression

causing

cell

death.

In

Myf-

5loxP/loxP;MyoDiCre/Neo embryos (C) the only factor driving myogenesis is Mrf4 and
produces the most 'normal' rib phenotype in comparison to the other genotypes.
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4.5 Discussion:

Given the preliminary status of these experiments, it is difficult to draw
many concrete conclusions. However, given the striking phenotype when the
MyoD expressing lineage is ablated,

it can be assumed that every cell in the

myogenic lineage activates the MyoD locus during embryonic development. This
follows closely on the heels of the finding that all satellite cells activate the MyoD
locus during embryogenesis (Kanisicak et al., 2009). As an endpoint assay, it is
striking to find no differentiated muscle at E18.5 in MyoDiCre/+;R26DTA embryos. A
detailed timeline of DTA dependent cell death needs to be performed in order to
fully characterize this phenomenon.
When analyzing the MyoDiCre/+;R26DTA E18.5 embryos, the rib phenotype
was impossible to miss. The lack of skeletal muscle and limb phenotype was
identical to the MyoDiCre/Neo;Myf-5Neo/Neo;R26lacZ phenotype described in chapter
2, yet rib growth was much more pronounced, although still extremely poor in
respect to wild type embryos.

The different rib phenotypes in the three

genotypes analyzed, where myogenesis is disrupted at various time points,
supports the hypothesis that rib growth is dependent on the myotome.
MyoDiCre/Neo;Myf-5Neo/Neo embryos have silenced Mrf4 expression, lack myoblast
and myotome formation, and have the most severe rib truncation phenotype as
myogenesis never begins (Kablar et al., 2003; Rudnicki et al., 1993).

In

MyoDiCre/+;R26DTA embryos, early myotome formation occurs, under the control
of Myf-5 and Mrf4, until MyoD is activated at approximately E10, after which, all
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muscle and myoblasts die and rib outgrowth stops. This window of myogenesis
appears to allow for more rib development. In the third genotype examined, Myf5loxP/loxP;MyoDiCre/Neo embryos have only Mrf4 to drive early myogenesis, which is
not enough to form viable newborn mice (Kassar-Duchossoy et al., 2004).
However, myogenesis occurs during embryogenesis and ribs develop much
more than any other genotype analyzed here. A more detailed analysis of these
animals during development will show exactly when myogenesis fails and
confirm signaling disruption between the sclerotome and myotome, and the
resulting axial skeleton defects linked to those genotypes.
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Chapter 5: Conclusions and Future Directions

5.1 Conclusions

All chapters of this thesis focus primarily on one member of the MRF gene
family, MyoD. In an attempt to refine the roles of the known cis-regulators of
MyoD transcription, the CE and DRR, we have shown these DNA elements are
not necessary to direct MyoD mRNA expression in a predominantly faithful
manner compared to wild type embryos. In embryos lacking the CE and DRR,
aside from an approximately one day delay in initiation of MyoD expression in the
limb buds and branchial arches, and a shorter delay in activation in the early
myotome, MyoD expression occurs normally during development. Knowing that
the vast majority of transcriptional regulation does not lie in the CE and DRR, or
the 15kb in between them, begins a new search for vital regulatory regions of this
important gene.
These current experimental outcomes are the epitome of necessity vs.
sufficiency. The CE (258bp) and DRR (720bp) are sufficient to activate and
maintain reporter gene transcription in a pattern nearly identical to MyoD's
expression profile (Chen et al., 2001; Goldhamer et al., 1995; Kablar et al.,
1999).

When these elements are deleted, we find they are not necessary for

proper regulation of the MyoD locus. We have shown that the recently published
reports focused on MyoD regulation via transcription factor binding to the CE are
incomplete as this element is quite disposable for proper regulation (Andrews et
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al., 2010; Havis et al., 2012; L'Honore et al., 2010; Yamamoto et al., 2007; Zhang
et al., 2011).

It should be noted that these studies looked much more deeply

into MyoD mRNA levels in their tissue or environment of interest than we did.
Our analysis ended at E12.5, when the global MyoD mRNA profile appeared
equivalent to wild type embryos.

Both of our new lines, MyoDΔCEDRR

and

MyoDΔCE15DRR, are viable and healthy, but they may exhibit unknown postnatal
transcriptional phenotypes.

The response these animals have to injury and

regeneration may also be affected, and should be investigated in the future.
Also, our genomic deletions have not led to improper, ectopic expression of
MyoD, leaving no known areas that are capable of repressing MyoD
transcription. The state of chromatin surrounding the MyoD locus may control
repression, as MyoD was discovered after demethylating fibroblasts, that in turn
activate the MyoD locus and form muscle (Taylor and Jones, 1979).
These findings ignite the search for new enhancer regions. The location of
possible enhancers abound, but based on the current knowledge of the locus,
one may be slightly upstream of the CE, where a portion of F3 fragment remains.
The F3 fragment has been shown to drive faithful reporter gene expression, and
part of this fragment contains the CE (Goldhamer et al., 1995; Goldhamer et al.,
1992)).

Another possible regulatory target are the introns of MyoD.

This

hypothesis is based on intronic enhancers in Myf-5 , sequence conservation
across species, putative binging sites for transcriptional activators, and
preliminary data from Dr. Yamamoto, whose work showed that replacement of
the open reading frame of MyoD with the GFP gene results in an unexpected
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absence of GFP in the myogenic lineage. Whether this result is an artifact of the
targeting design, or disruption of a new regulatory mechanism, should be
pursued. Intron 1 of MyoD appears to be involved in regulation also based on
H3K4 tri-methylation levels. A transgenic mouse embryo with intron one driving
a reporter gene’s expression can be performed to address that possibility.
Replacement of the MyoD gene with the MyoD cDNA in mouse embryos
will determine if introns are regulating MyoD expression. To begin an unbiased
search for enhancers, large scale BAC transgenes can be employed. The BACs
should contain the genomic DNA surrounding the MyoD gene and contain a
reporter gene, with its own minimal promoter. Large portions of the BAC can
then be removed, followed by integration into the genome of murine ESCs to
develop embryos and assayed for aberrant reporter gene expression. Ultimately,
the large deletions can be refined to discrete elements.

Chromatin

Immunoprecipitation can also be used to identify trans-acting regulators, which
are largely unknown, but several have been implicated in the introns of MyoD.
Many recent studies have show transcription factors of interest binding the CE,
but we now know that this interaction is not necessary for embryonic MyoD
expression, and other regions should be investigated.
Linage tracing experiments presented in this thesis show strong support
for MyoD being a determination factor in the trunk. Observation of cells that
normally would have contributed to skeletal muscle instead forming brown fat,
cartilage and bone in the absence of MyoD shows these cells are not determined
before MyoD expression. The interpretation is complicated due to the absence
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of the Myf-5 gene. In embryos lacking only MyoD, all recombined cells contribute
to the developing skeletal muscle. Based on the preliminary data in Chapter4
and Myf-5 lineage ablation studies (Gensch et al., 2008; Haldar et al., 2008),
some portion of the recombined cells presumably express only MyoD and not
Myf-5. These cells may have fused to Myf-5 dependent muscle.
The difference in phenotype of progenitors in the limb versus the trunk
should also be investigated. Trunk progenitors can assume various fates, yet
limb progenitors remain physically distinct from the surrounding fibroblastic
mesenchyme, yet some express markers of the mesenchyme. FACS isolation of
recombined cells that arrive in the limb at different time points can be used for
heterotopic transplantation to further assess the determination status of these
cells.

Due to the long range migration, and lack of MRF expression before

reaching the limb field, these cells may be strongly specified to the myogenic
lineage while in the somite. The contribution of labeled cells to bone in the trunk
may be due to both lineages arising from paraxial mesoderm. In the limb, bone
progenitors come from the lateral plate mesoderm, and may be somehow
refractory to contribution from somitically derived cells.
Also, if the genotype were changed such that the Myf-5loxP allele replaces
the Myf-5Neo allele, information regarding Mrf4 dependent myogenesis could be
uncovered.

In this scheme, Mrf4 expression is not compromised and

myogenesis occurs, but not to the extent of myogenic rescue (Kassar-Duchossoy
et al., 2004).

Looking for a fate change of the recombined cells in an embryo

with some myogenesis would be informative as to the overlap between Mrf4 and
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MyoD expression. I would like to see if the recombined cells all contribute to the
muscle, or if some still escape and become fat or cartilage. The limb field is of
particular interest, as minimal reports are available on the limb phenotype in
MyoD/Myf-5 double mutants when the Mrf4 locus is unperturbed.
The MyoDiCre;R26DTA results add support to the new theory that all
myogenic progenitors express MyoD during development.

Previous reports

imply that there is a Myf-5 dependent lineage and a Myf-5 independent lineage.
Now that all myoblasts and satellite cells (Kanisicak et al., 2009) express MyoD
prenatally, it is even more interesting that MyoD null animals are viable and have
reasonably normal muscle. Some uncertainty exists when comparing Myf-5Cre
studies to the current MyoDiCre studies. The Myf-5Cre allele may be ectopically
expressed. Given the sensitivity of the Myf-5 locus to targeting, cells that should
activate the allele may not, while other may activate it when inappropriate.

We

have internally tested the MyoDiCre allele for specificity, and it appears to faithfully
mimic MyoD mRNA expression.
The observation that the longer the myotome exists, the more complete rib
development

occurs

requires

extensive

experimental

refinement.

A

developmental time courses during embryogenesis is needed to analyze exactly
when myotome growth, and the resulting intercostal muscles, starts and stops in
the various genotypes used in these preliminary studies. Our endpoint assay
only shows a correlation, and is light on cause and effect. Others have reported
that PDGFR alpha and FGF signaling between the myotome and sclerotome is
disrupted when the myotome is absent and this is the cause of the rib phenotype
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(Tallquist et al., 2000).

Detection of these growth factors should be performed

during development in the three genotypes analyzed here. Also of interest is a
study that shows terminal rib malformations in embryos lacking the two
differentiation factors, Mrf4 and a reduced function version of Myogenin (Vivian et
al., 2000).

This supports the hypothesis that myotome formation and

the

maintenance of muscle is needed throughout rib development.
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